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ABSTRACT 
 
THE TOXIC INTERACTION OF DOPAMINE AND ALPHA-SYNUCLEIN: 
IMPLICATIONS FOR PARKINSON’S DISEASE 
Danielle Emille Mor 
Harry Ischiropoulos 
 
Neurodegenerative disorders are characterized by the death of specific neuronal 
populations and the aggregation of particular proteins into pathological inclusions.  The 
role of protein aggregation and the factors that govern neuronal susceptibility to disease 
have remained unclear.  In Parkinson’s disease (PD), the loss of dopamine producing 
neurons in the substantia nigra (SN) leads to severe motor impairments, and the protein 
α-synuclein is found aggregated in several brain regions including the SN.  The goal of 
this thesis was to investigate a possible mechanism for the vulnerability of dopaminergic 
neurons: the interaction of α-synuclein with dopamine itself.  While dopamine has been 
suspected to contribute to cell death in PD by causing oxidative stress, I found using a 
lentiviral approach that a long-term increase of dopamine levels in non-transgenic mice 
was insufficient to produce dopamine neuron loss.  In contrast, elevating dopamine in 
mice expressing human α-synuclein resulted in progressive nigrostriatal degeneration and 
an associated locomotor deficit.  These findings demonstrate that dopamine toxicity is 
dependent on α-synuclein.  To explore a possible point of convergence of these two 
factors, I examined the effects of dopamine on α-synuclein aggregation in the mouse 
brain.  This led to the novel observation that dopamine increases total steady-state levels 
 vi 
of α-synuclein oligomers and promotes modified oligomeric conformations.  α-Synuclein 
oligomers generated in the presence of dopamine in vitro were biochemically similar to 
mouse-derived species and were found to be toxic to primary neurons.  Taken together, 
these data provide evidence that dopamine-induced α-synuclein oligomers may underlie 
the susceptibility of dopaminergic neurons in disease. 
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INTRODUCTION 
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1.1  Introduction 
Neurodegenerative diseases are clinically and pathologically distinct, and yet 
share many fundamental features that suggest common underlying mechanisms.   
Diseases such as Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD) and 
amyotrophic lateral sclerosis (ALS) are typically late-onset and progressive, leading to 
debilitating cognitive and/or motor deficits.  Despite differences in clinical presentation 
and the specific neuronal populations that are lost, neurodegenerative disorders share a 
common pathological hallmark, the presence of proteinaceous inclusions in the central 
nervous system.  The regional and subcellular localization of these lesions differs in each 
disease, as well as the major protein constituents.  In AD, extracellular senile plaques 
consist of the peptide amyloid-β (Glenner and Wong, 1984), and intraneuronal 
neurofibrillary tangles contain the microtubule-associated protein tau (Lee et al., 1991).  
In PD and related disorders, the hallmark pathological substrates are Lewy bodies and 
Lewy neurites, cytoplasmic inclusions containing the presynaptic protein α-synuclein 
(Spillantini et al., 1997).  Intranuclear aggregates in HD are comprised of the protein 
huntingtin (DiFiglia et al., 1997), whereas the majority of ALS patients develop TDP-43 
positive inclusions (Neumann et al., 2006).  
Despite extensive research efforts, the relationship of aggregation and 
neurodegeneration remains unclear.  The neuronal populations that harbor inclusion 
pathology only partially overlap with those that undergo cell death, and the density of 
inclusions is only weakly correlated with the severity of clinical symptoms (Ross and 
Poirier, 2005).  While it was originally thought that large intracellular deposits 
compromise neuronal health, more recently it has been recognized that inclusions may 
 3 
serve a protective role as a sink for more toxic aggregation intermediates.  Indeed, small 
aggregates termed oligomers have emerged as potentially a major pathogenic species in 
multiple neurodegenerative disorders (Kayed et al., 2003).  The discovery of causative 
genetic mutations in families afflicted with these disorders has allowed for the 
development of genetic animal and cellular models, greatly advancing our understanding 
of the molecular mechanisms involved in neurodegeneration.  In many cases, the genes 
linked to disease encode the characteristic proteins found aggregated within inclusions, 
further implicating protein aggregation in disease pathogenesis (Lill and Bertram, 2011).  
Continued investigation is required to uncover the complex interactions between protein 
aggregates and cellular machinery that lead to neuron death, and to develop new therapies 
to combat these devastating diseases for which there is currently no cure.  
 
1.2  Synucleinopathies  
α-Synuclein aggregation into insoluble filamentous inclusions is a central 
pathological feature of diseases collectively referred to as synucleinopathies, including 
PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).  In 1912, 
Fritz Heinrich Lewy published the first descriptions of intraneuronal proteinaceous 
inclusions in PD patient brains (Lewy, 1912), which were later named after him 
(Tretiakoff, 1919).  In 1997, following the discovery of a PD-linked mutation in the gene 
encoding α-synuclein (Polymeropoulos et al., 1997), it was found that Lewy bodies and 
analogous deposits in neural projections, Lewy neurites, are robustly immunoreactive for 
α-synuclein even in sporadic disease (Spillantini et al., 1997).  These seminal findings 
heralded a new era of research on the role of α-synuclein in neurodegenerative diseases.   
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1.2.1 α-Synuclein structure and function 
α-Synuclein is a small (140 residues) highly conserved protein that is abundantly 
expressed in brain and in part localized to presynaptic nerve terminals (Maroteaux et al., 
1988; Jakes et al., 1994; Iwai et al., 1995).  The physiological functions of α-synuclein 
appear to involve synaptic maintenance and plasticity (George et al., 1995; Withers et al., 
1997), regulation of synaptic vesicle pools (Murphy et al., 2000; Nemani et al., 2010), 
and SNARE complex assembly (Chandra et al., 2005; Burré et al., 2010).  Transgenic 
mice lacking α-synuclein have normal neuronal and synaptic development, though subtle 
deficits in dopamine release suggest a role in synaptic vesicle recycling (Abeliovich et 
al., 2000; Cabin et al., 2002; Yavich et al., 2004).  While the native conformation of α-
synuclein is under debate (Weinreb et al., 1996; Bartels et al., 2011; Wang et al., 2011; 
Fauvet et al., 2012a; Gould et al., 2014), its sequence and proximity to synaptic vesicles 
suggest that interactions with vesicular membranes may be important for its biological 
activity.  Specifically, the N-terminal region contains seven imperfect repeats with a 
consensus motif of KTKEGV, resembling the lipid binding domain of apolipoproteins 
(George et al., 1995; Maroteaux et al., 1988).  This region mediates acquisition of α-
helical structure that occurs upon α-synuclein binding to lipid membranes in vitro 
(Davidson et al., 1998).  Amino acids 61-95 make up the hydrophobic NAC (non-
amyloid-β component of Alzheimer’s disease amyloid) domain (Uéda et al., 1993), which 
is necessary for aggregation (Giasson et al., 2001).  The C-terminal region is highly 
acidic and contains known sites of protein-protein interactions, metal binding, and post-
translational modifications (Uversky et al., 2001a; Woods et al., 2007; Oueslati et al., 
2010).  For a detailed review of α-synuclein native structure and function see Chapter 3. 
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1.2.2 α-Synuclein pathology in disease 
Significant clinical and pathological overlap between synucleinopathies suggests 
they may share common underlying mechanisms driven by α-synuclein toxicity.  PD and 
MSA are primarily movement disorders, characterized by resting tremor, muscle rigidity, 
bradykinesia, and postural instability (collectively termed parkinsonism) (Hoehn and 
Yahr, 1967).  DLB is also defined by parkinsonian symptoms, as well as prominent 
dementia that develops within one year of motor dysfunction (McKeith et al., 2005). 
While PD and DLB have largely indistinguishable Lewy body pathology in brainstem 
nuclei, DLB more commonly involves widespread cortical Lewy bodies, which may 
underlie the presentation of dementia (Kosaka, 1978; Lennox et al., 1989; McKeith et al., 
1996; Spillantini et al., 1997).  Senile plaques characteristic of AD are usually present in 
the cortex in DLB (Lennox et al., 1989), and conversely AD patients often have Lewy 
bodies in the amygdala (Kotzbauer et al., 2001).  MSA is an atypical synucleinopathy in 
that α-synuclein-positive inclusions are present in oligodendrocytes rather than neurons, 
and are termed glial cytoplasmic inclusions (GCIs) (Papp et al., 1989; Wakabayashi et 
al., 1998; Spillantini et al., 1998a; Tu et al., 1998).  GCIs are found in diverse areas of the 
brain, including the neocortex, hippocampus, midbrain, brainstem, and cerebellum 
(Arima et al., 1992; Duda et al., 2000). 
 Inclusion pathology has been extensively studied both histologically and 
biochemically from postmortem diseased human brain.  Lewy bodies are classically 
defined as eosinophilic structures with a dense core surrounded by a diffuse halo; 
however, while this description is suitable for brainstem inclusions, cortical Lewy bodies 
have a less distinct appearance (Pollanen et al., 1993; Forno, 1996).  α-Synuclein, but 
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not the related β-synuclein, has been identified as an integral component of Lewy bodies 
using a multitude of antibodies (Spillantini et al., 1997; 1998b; Takeda et al., 1998; Baba 
et al., 1998; Irizarry et al., 1998; Giasson et al., 2000a; Crowther et al., 2000).  By 
electron microscopy, α-synuclein filaments from diseased brain appear unbranched, are 
typically 5-10 nm in width, and can reach hundreds of nm in length (Spillantini et al., 
1998b).  Several modifications have been identified in α-Synuclein isolated from Lewy 
bodies, including phosphorylation at Ser-129 and Ser-87, ubiquitination at Lys-12, Lys-
21, and Lys-23, and C-terminal truncations (Fujiwara et al., 2002; Hasegawa et al., 2002; 
Anderson et al., 2006; Paleologou et al., 2010).  In addition, tyrosine-nitrated α-synuclein 
is widespread in the brains of synucleinopathy patients (Giasson et al., 2000b).  For a 
review of α-synuclein post-translational modifications in vivo and in vitro, see Chapter 3.  
Lewy body inclusions also contain other proteins, including neurofilaments, proteasomal 
subunits, and synaptophysin (Goldman et al., 1983; Schmidt et al., 1991; Ii et al., 1997; 
Takeda et al., 1998), as well as lipids (Gai et al., 2000).  
 
1.2.3 α-Synuclein aggregation pathway 
The fibrillar morphologies of synucleinopathy lesions have been recapitulated in 
numerous studies using recombinant α-synuclein in vitro.  Like amyloids in AD and other 
diseases, α-synuclein is able to form amyloid-like fibrils, which are rich in β-pleated 
sheets and produce characteristic signals upon binding Thioflavin T and Congo Red dyes.  
Recombinant α-synuclein fibrils have been observed by numerous imaging and 
biochemical methodologies, including electron and atomic force microscopy, circular 
dichroism, solid-state nuclear magnetic resonance and infrared spectroscopy, and 
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gel electrophoresis (Conway et al., 1998; 2000a; Hashimoto et al., 1998; Giasson et al., 
1999; Serpell et al., 2000; Tuttle et al., 2016).  In vitro, the formation of fibrils follows a 
classical polymerization reaction, including a lag phase with little detectable fibril 
formation, followed by a growth phase with rapid polymerization.  The rate-limiting step 
in α-synuclein fibrillization is thought to be the initial formation of a nucleus, likely an 
oligomer or small polymer of α-synuclein molecules (Wood et al., 1999; Uversky et al., 
2001b).  A schematic of the aggregation pathway of α-synuclein is depicted in Figure 1.1.  
 
1.3  Parkinson’s disease 
PD is the most common age-associated movement disorder, affecting 7 million 
people worldwide and predicted to significantly increase in prevalence as the population 
ages (Van Den Eeden et al., 2003; de Lau and Breteler, 2006).  The parkinsonian motor 
features that were first described by James Parkinson in 1817 arise from progressive loss 
of dopaminergic neurons in the substantia nigra pars compacta (SN) (Parkinson, 1817; 
Tretiakoff, 1919; Hassler, 1938).  While diagnosis of PD is contingent on the presentation 
of motor signs, it is increasingly recognized that the PD clinical profile involves non-
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motor features as well.  Sleep disturbances, autonomic dysfunction, hyposmia, and 
depression may appear decades prior to the onset of motor impairment (Lim et al., 2009).  
Dementia is also common, typically in advanced PD (Reid et al., 2011).  The loss of 
extranigral neuronal populations may underlie non-motor symptoms.  In the brainstem, 
noradrenergic neurons of the locus coeruleus are particularly affected.  Cholinergic cells 
are also lost, both in the dorsal motor nucleus of the vagus in the brainstem and nucleus 
basalis of Meynert in the basal forebrain (Forno, 1996).  PD is therefore considered a 
complex disorder involving multiple brain regions and neurotransmitter systems. 
 
1.3.1 Basal ganglia dysfunction in PD 
 The death of dopaminergic cells in PD leads to a severe depletion of dopamine at 
the main site of SN innervation, the dorsal striatum (Ehringer and Hornykiewicz, 1960).  
The SN and striatum are found within the basal ganglia, a group of subcortical structures 
that serve as a critical regulator of motor output.  The classical model of basal ganglia 
circuitry describes three major pathways: the direct pathway, which is thought to promote 
selected motor programs, and the indirect and hyperdirect pathways, which are thought to 
simultaneously oppose competing motor programs (Wichmann et al., 2011).  As depicted 
in Figure 1.2, the direct pathway involves cortical excitation of striatal neurons, which in 
turn disinhibit thalamocortical circuits resulting in greater excitation of motor neurons.  
The indirect pathway instead disinhibits the subthalamic nucleus, causing excitation of 
the globus pallidus interna and suppression of thalamocortical activity (Albin et al., 1989; 
DeLong, 1990).  The hyperdirect pathway bypasses the striatum and directly excites the 
subthalamic nucleus, dampening the activity of motor neurons (Nambu et al., 2000).   
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Dopamine serves as an important modulator of this complex circuitry.  Spiny 
projection neurons in the striatum express G-protein coupled dopamine receptors of 
either the D1- or D2-type.  Neurons in the direct pathway express D1-type receptors, 
which mediate an increase in intrinsic excitability upon activation by dopamine, and 
promote long-term potentiation.  Indirect pathway neurons express D2-type receptors and 
have the opposite response when bound by dopamine, promoting long-term depression.  
The loss of striatal dopamine in PD is therefore thought to result in reduced activity of the 
direct pathway and increased activity of the indirect pathway, accounting for the overall 
reduction of movement (Surmeier et al., 2014).  While this model of basal ganglia 
circuitry and its dysfunction in PD has proved useful, it was recently proposed that the 
direct and indirect pathways may actually be much more integrated both structurally and 
functionally (Calabresi et al., 2014).  
 
1.3.2 Genetics of PD 
 While PD is rarely 
inherited (~10% of all cases), 
genetic mutations identified in 
families with the disease offer 
insight into the mechanisms 
underlying the sporadic dis-
order.  Several genes are now 
linked with highly penetrant, 
monogenic forms of PD, 
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including the gene encoding α-synuclein, SNCA, as well as LRRK2, Parkin, DJ-1, 
PINK1, UCHL1, ATP13A2 and VPS35, and numerous genetic risk factors have 
additionally been identified (Hernandez et al., 2016).  The A53T missense mutation in 
SNCA was the first genetic link identified, specifically in autosomal dominant early-onset 
PD (Polymeropoulos et al., 1997).  Since this discovery, additional mutations in SNCA 
have been found to cause PD: A30P, E46K, H50Q, G51D, and most recently A53E 
(Krüger et al., 1998; Zarranz et al., 2004; Proukakis et al., 2013; Lesage et al., 2013; 
Pasanen et al., 2014).  These mutants are all located within the N-terminal region that is 
required for membrane binding, and in many cases exhibit altered aggregation kinetics 
and lipid interactions in vitro (Conway et al., 1998; Jensen et al., 1998; Giasson et al., 
1999; Choi et al., 2004; Ghosh et al., 2014; Khalaf et al., 2014; Fares et al., 2014).  
Multiplications of the SNCA gene locus also cause early-onset PD, with increasing copy 
number correlating with earlier age of onset and greater severity of symptoms, suggesting 
that increased expression of wild type (WT) α-synuclein is detrimental (Singleton et al., 
2003; Chartier-Harlin et al., 2004; Ferese et al. 2015).   
 Mutations in LRRK2 result in autosomal dominant PD and are the most common 
cause of familial cases (Zimprich et al., 2004; Paisan-Luiz et al., 2004).  The G2019S 
mutation is the most well-studied; it is located in the kinase domain of LRRK2 and 
results in increased kinase activity.  At present, the pathophysiological mechanisms of 
LRRK2 toxicity are unclear (Hernandez et al., 2016).  Several of the other genes linked to 
PD induce a early-onset, autosomal recessive form of the disease (Kitada et al., 1998, 
Valente et al., 2004, Bonifati et al., 2003) and are functionally related in the cellular 
response to mitochondrial damage.  Parkin is an E3 ubiquitin ligase that is 
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translocated to defective mitochondria where it is phosphorylated by PINK1.  This 
stimulates parkin to ubiquitinate multiple substrates, leading to the clearance of 
mitochondria by autophagy (Park et al., 2006; Clark et al., 2006).  DJ-1 may also function 
in this pathway, though its role is much less clear.  It is thought that mutations in Parkin, 
PINK1, and DJ-1 are responsible for disease through a loss-of-function mechanism 
(Goedert et al., 2013).  Interestingly, autosomal recessive PD is not characterized by 
Lewy body pathology, possibly due to the young age of onset (Hernandez et al., 2016).  
Further investigation is necessary to better understand the role of α-synuclein in this form 
of PD. 
 
1.3.3 Genetic animal models of α-synuclein toxicity 
 α-Synuclein expression in animal model systems has provided key insights into 
the complex relationship between aggregation and neurodegeneration.  In monkeys and 
rats, viral-mediated expression of WT or A53T mutant human α-synuclein in the SN 
resulted in a progressive neurological disease that recapitulated the cardinal features of 
PD.  The formation of intracellular α-synuclein positive inclusions and neuritic pathology 
was accompanied by the selective loss of 30-80% of dopaminergic neurons and the 
development of motor deficits (Lo Bianco et al., 2002; Kirik et al., 2002; 2003).  
Similarly, expression of A30P human α-synuclein in the rat SN caused dense α-synuclein 
accumulations and over 50% loss of dopamine neurons.  Motor impairments were not 
detected in these rats, however (Klein et al., 2002), consistent with a threshold of about 
70% neuron loss for movement symptoms to appear in humans (Dunnett and Bjorklund, 
1999).  
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Efforts to model PD by transgenic overexpression of α-synuclein in mice have 
yielded mixed results.  Expression of WT α-synuclein under the PDGF-β promoter 
resulted in atypical non-fibrillar α-synuclein inclusions and reduced TH immuno-
reactivity in the striatum without overt dopaminergic cell loss (Masliah et al., 2000).  In 
mice expressing human WT or familial mutants (A30P, E46K, or A53T) of α-synuclein 
under the PrP promoter, the SN was consistently spared of both neurodegeneration and α-
synuclein inclusion pathology, despite the development of Lewy body-like inclusions in 
other regions specifically in A53T transgenic mice (Giasson et al., 2002; Lee et al., 2002; 
Gispert et al., 2003; Gomez-Isla et al., 2003; Yavich et al., 2005; Martin et al., 2006; 
Emmer et al., 2011).  Similarly, Thy1-driven expression of human A30P α-synuclein did 
not result in histopathological changes or neuron loss in the SN, possibly due to low 
levels of transgene expression (Rathke-Hartlieb et al., 2001; Neumann et al., 2002).  
Targeting WT, A30P, or A53T human α-synuclein expression specifically to 
dopaminergic neurons using the TH promoter was insufficient to produce either 
nigrostriatal degeneration or Lewy body-like α-synuclein pathology (Rathke-Hartlieb et 
al., 2001; Matsuoka et al., 2001; Richfield et al., 2002).  Greater success inducing 
dopaminergic cell death was achieved using bacterial artificial chromosome transgenic 
mice expressing human WT α-synuclein (Janezic et al., 2013) or by conditional 
expression of human WT or A53T α-synuclein (Nuber et al., 2008; Lin et al., 2012).  
(The previous paragraph is taken from Mor et al., manuscript under revision). 
Invertebrates have offered simple yet powerful platforms for conducting 
mechanistic studies of α-synuclein toxicity.  In flies, targeted expression of WT, A30P, or 
A53T human α-synuclein in the nervous system produces filamentous α-synuclein 
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inclusions, neurodegeneration of dopamine cells, and an impairment in climbing ability 
(Feany et al., 2000).  Co-expression of α-synuclein with the chaperone Hsp70 was found 
to rescue neuron death without reducing inclusion pathology, suggesting that the presence 
of inclusions can be uncoupled from toxicity.  Furthermore, co-expression of a dominant-
negative mutant of Hsp70 with α-synuclein resulted in accelerated degeneration, 
emphasizing the role of chaperone activity in maintaining neuronal health (Auluck et al., 
2002).  In another study, expressing non-fibrillogenic α-synuclein lacking residues 71-82 
was non-toxic to dopamine neurons, unlike WT α-synuclein, while aggregation-prone 
truncation mutants exacerbated toxicity (Periquet et al., 2007).  C. elegans expressing 
human α-synuclein in dopaminergic neurons have exhibited variable phenotypes.  In 
some cases, WT or A53T α-synuclein transgenic worms showed dopamine neuron loss 
(Lakso et al., 2003; Cao et al., 2010), whereas in another study, neurite degeneration 
without overt cell loss was reported in WT, A30P, and A53T worms (Kuwahara et al. 
2006).  Motor deficits were sometimes observed and could be rescued by administration 
of dopamine (Kuwahara et al. 2006; Cao et al., 2010).  Finally, there is some evidence for 
α-synuclein accumulations in these worms (Lakso et al., 2003; Kuwahara et al. 2006); 
however it is unclear whether these structures are the result of α-synuclein aggregation.   
 
1.3.4 Prion-like spread of α-synuclein pathology in PD 
 The progressive buildup of α-synuclein pathology in PD is suggestive of the 
spread of disease agent(s), potentially originating in the gut and ultimately reaching the 
central nervous system.  Evidence suggests that early in the disease course, α-synuclein 
positive inclusions form in the enteric nervous system (Braak et al., 2006).  The 
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vagal nerve serves as a major connection between the brain and the periphery, and 
consistent with cell-to-cell transmission of pathology, the dorsal motor nucleus of the 
vagus is among the earliest brain regions to become affected in PD (Braak et al., 2003).  
Braak and colleages have defined six stages of PD based on the stereotypical distribution 
of Lewy pathology.  In the initial stages, in addition to the dorsal motor nucleus, the 
anterior olfactory nucleus develops α-synuclein positive inclusions, as well as the raphe 
nuclei and locus coeruleus.  As PD advances, the midbrain becomes involved and finally 
cortical regions such as sensory association areas (Braak et al., 2003).  The development 
of Lewy pathology may account for disease symptoms, in that inclusions are usually 
present in the SN by the time motor dysfunction has manifested, and neocortical lesions 
occur in late stages often accompanied by dementia (Goedert et al., 2013). 
 Several lines of evidence support prion-like transmission of α-synuclein in PD 
and other neurodegenerative diseases (see Table 1).  Post-mortem studies of PD patients 
who received fetal mesencephalic grafts into the striatum showed that 11-16 years 
following transplantation, grafted neurons contained Lewy body-like α-synuclein 
inclusions (Li et al., 2008; Kordower et al., 2008).  Given the young age of the grafted 
cells, it is unlikely that pathology developed independent of exposure to α-synuclein 
and/or other factors from diseased host tissue.  In animal models, intracerebal inoculation 
of recombinant α-synuclein pre-formed fibrils (PFFs), brain tissue from symptomatic 
A53T α-synuclein transgenic mice, or brain tissue from synucleinopathy patients results 
in widespread deposition of Lewy body-like α-synuclein inclusions often accompanied 
by neurodegeneration and motor deficits.  Moreover, it appears that, regardless of the site 
of injection, aggregation propagates along synaptic connections and requires the 
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presence of endogenous α-synuclein (Luk et al., 2012a; 2012b; Masuda-Suzukake et al 
2014; Watts et al., 2013; Recasens et al., 2013; Paumier et al., 2015; Sacino et al., 2014b; 
Peelaerts et al., 2015).  Several studies have also demonstrated the spread of α-synuclein 
pathology from peripheral sites to the central nervous system, using intravenous 
(Peelaerts et al., 2015), intramuscular (Sacino et al., 2014a), or intraperitoneal (Breid et 
al., 2016) injections of recombinant α-synuclein aggregates into rodents.  α-Synuclein 
aggregation in vitro is also prion-like, exhibiting self-templated replication or ‘seeding’ 
via the repeated conversion of soluble protein into misfolded conformations (Conway et 
al., 1998; Wood et al., 1999). 
 While these studies provide compelling evidence that aggregated α-synuclein is 
sufficient to induce neurological disease bearing the hallmarks of synucleinopathies, even 
in otherwise healthy non-transgenic animals, many questions still remain.  The injection 
of α-synuclein PFFs into mouse brain does not always lead to the spreading of pathology 
(Sacino et al., 2013; 2014b), indicating that host-dependent susceptibility must be further 
explored.  Also, the induction of pathology may not require that the initiating α-synuclein 
agent be fibrillized, as recombinant monomeric α-synuclein and mutant α-synuclein 
lacking amino acids 71-82 in the NAC domain were able to produce inclusions in some 
recipient animals (Sacino et al., 2013; 2014a; Paumier et al., 2015).  Finally, it is possible 
that factors other than α-synuclein contribute to inclusion formation, since spinal cord 
tissue from non-transgenic mice or mice lacking endogenous α-synuclein was able to 
induce pathology following intracerebral injection (Sacino et al., 2016).   
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Table 1.1: Major evidence for prion-like transmission of α-synuclein (agent) in cell 
culture and animal models (host). 
Agent Host Findings Reference 
Recombinant 
human α-synuclein 
oligomers and 
PFFs of two 
distinct strains 
(fibrils or ribbons) 
NonTg and human 
α-synuclein 
expressing rats, 
injected into SN 
 
 
NonTg rats, inject-
ed intravenously  
By 4 mpi, only ribbons induced abundant      
α-synuclein aggregation. Nigrostriatal 
degeneration was dependent on α-synuclein 
expression and was most severe for fibrils. 
Fibrils also induced motor impairment.  
 
By 4 mpi, α-synuclein positive inclusions 
detected in spinal cord and cortex. 
Peelaerts 
et al., 
2015 
Recombinant 
human and mouse 
α-synuclein PFFs 
Non-symptomatic 
A53T, WT human 
α-synuclein Tg 
mice injected into 
hindlimb muscle 
By 2-4 mpi, A53T Tg mice developed wide-
spread α-synuclein aggregation in the central 
nervous system and motor deficits. By 12 mpi, 
WT Tg mice developed α-synuclein pathology 
without motor deficit. 
Sacino et 
al., 2014a 
PD tissue from SN 
containing 
insoluble LBs  
Macaque monkeys, 
injected into SN or 
striatum 
 
NonTg mice, 
injected into SN 
By 9 mpi, loss of striatal terminals. By 14 
mpi, dopamine neuron death and diffuse  
α-synuclein deposits in SN. 
 
By 4 mpi, loss of striatal terminals, dopamine 
neuron death in SN, diffuse accumulations 
containing phosphorylated α-synuclein in SN. 
Recasens 
et al., 
2013 
MSA basal ganglia 
tissue containing 
insoluble GCIs 
 
 
Brain tissue from 
symptomatic A53T 
human α-synuclein 
Tg mice 
Non-symptomatic 
A53T human α-
synuclein Tg mice, 
injected into cortex 
 
Non-symptomatic 
A53T human α-
synuclein Tg mice, 
injected into cortex 
By ~3-4 mpi, neurological disease onset and 
widespread aggregates containing phosphory-
lated α-synuclein.  
 
 
By ~6-7 mpi, neurological disease onset and 
widespread aggregates containing phosphory-
lated α-synuclein. 
 
Watts et 
al., 2013 
DLB brain tissue 
containing insol-
uble α-synuclein 
 
Recombinant 
human and mouse 
α-synuclein PFFs 
NonTg mice, 
injected into SN 
 
 
NonTg mice, 
injected into SN 
By 15 mpi, widespread aggregates containing 
phosphorylated α-synuclein 
 
 
By 15 mpi, widespread aggregates containing 
phosphorylated α-synuclein, without 
accompanying neuron loss or motor deficit 
Masuda-
Suzukake 
et al., 
2013 
Recombinant 
human α-synuclein 
PFFs of two 
distinct strains  
(A or B) 
Mutant tau Tg 
mice, injected into 
hippocampus 
 
Primary neurons 
from NonTg or 
mutant tau Tg mice 
 
At 3, 6, and 9 mpi, strain B more efficiently 
cross-seeded tau than strain A. 
 
 
Strain A was toxic, seeded abundant α-
synuclein aggregation without cross-seeding 
tau. Strain B was non-toxic, cross-seeded tau, 
seeded α-synuclein less efficiently than A. 
Guo et al., 
2013 
Recombinant 
mouse α-synuclein 
PFFs 
NonTg mice, 
injected into 
striatum 
By 1 mpi, widespread endogenous α-
synuclein aggregation. By 3 and 6 mpi, further 
spread of aggregation, neuron death in SN, 
and motor deficits. 
Luk et al., 
2012b 
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Brain tissue from 
symptomatic A53T 
human α-synuclein 
Tg mice  
 
 
Recombinant 
human α-synuclein 
PFFs 
 
Non-symptomatic 
A53T human α-
synuclein Tg mice, 
injected into cortex 
or striatum 
 
Non-symptomatic 
A53T human α-
synuclein Tg mice, 
injected into cortex 
or striatum 
Accelerated neurological disease onset, 
widespread aggregates containing phosphory-
lated α-synuclein, reduced survival 
 
 
 
Accelerated neurological disease onset, 
widespread aggregates containing phosphory-
lated α-synuclein, reduced survival 
Luk et al., 
2012a 
WT human α-
synuclein Tg mice  
 
 
Recombinant  
α-synuclein PFFs, 
oligomers, or 
monomers  
 
HEK or SH-SY5Y 
cultures expressing 
tagged α-synuclein, 
conditioned media  
 
Recombinant  
α-synuclein PFFs, 
oligomers, or 
monomers  
Mouse fetal mid-
brain neurons, inj-
ected into striatum 
 
WT human α-
synuclein Tg mice, 
injected into cortex 
 
 
HEK or SH-SY5Y 
cultures expressing 
different tag on  
α-synuclein 
 
HEK cultures 
 
 
By 6 mpi, human α-synuclein from Tg mice 
detected in grafted cells 
 
 
By 1 day post-injection with PFFs or oligo-
mers, intracellular puncta of α-synuclein. 
Diffuse α-synuclein 1 dpi with monomers. 
 
 
Up to 14 days in culture, cells containing 
double-labeled α-synuclein were detected  
 
 
 
By 3 hours post-treatment, exogenous α-
synuclein was detected in cells regardless of 
aggregation state administered 
 
Hansen et 
al., 2011 
Recombinant 
human α-synuclein 
PFFs 
Primary neurons 
from NonTg mice 
By 14 days post-treatment, exogenous  
α-synuclein was internalized by cells, seeded 
aggregation of endogenous α-synuclein, and 
induced synaptic dysfunction and cell death 
Volpicelli-
Daley et 
al., 2011 
WT human α-
synuclein Tg mice  
 
 
SH-SY5Y cultures 
expressing human 
α-synuclein, or 
conditioned media 
Mouse neuronal 
stem cells, injected 
into hippocampus 
 
Primary neurons or 
neuronal stem cells 
from mice or rats, 
or SH-SY5Y cells 
Up to 1 mpi, human α-synuclein detected in 
non-fibrillar aggregates in grafted stem cells, 
and markers of apoptosis 
 
Up to 3 days in culture, detected intracellular 
aggregates containing exogenous α-synuclein, 
and markers of apoptosis  
Desplats 
et al., 
2009 
Recombinant 
human α-synuclein 
PFFs 
QBI-HEK, HeLa, 
and SH-SY5Y 
cultures expressing 
human α-synuclein 
By 1 day post-treatment, exogenous α-
synuclein seeded aggregation of endogenous 
α-synuclein 
Luk et al., 
2009 
Abbreviations: DLB, Dementia with Lewy bodies; GCI, glial cytoplasmic inclusion; LB, Lewy body; mpi, 
months post-injection; MSA, multiple system atrophy; NonTg, non-transgenic; PD, Parkinson’s disease; 
PFF, pre-formed fibrils; SN, substantia nigra; Tg, transgenic; WT, wild type. 
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1.3.5 Pharmacologic therapies 
Efforts to treat PD patients have centered on restoring dopaminergic signaling in 
the striatum.  Administration of the dopamine precursor, L-3,4-dihydroxyphenylalanine 
(L-DOPA), was the first treatment developed for PD (Birkmayer and Hornykiewicz, 
1961) and remains the most effective therapy to date.  However, prolonged use of          
L-DOPA can have significant side effects, such as motor fluctuations and dyskinesia 
(Olanow, 2015).  Other dopamine replacement therapies include dopamine receptor 
agonists and inhibitors of dopamine metabolism (Kakkar et al., 2015).  While these 
therapeutic strategies can provide symptomatic relief, there is currently no cure for the 
relentless loss of dopaminergic neurons in PD. 
 
1.4  Dopamine as a neurotoxic molecule 
 Despite the clinical benefit of augmenting dopamine levels in PD patients, it has 
long been suspected that dopamine may in fact contribute to the development of disease 
(Fahn and Cohen, 1992; Jenner and Olanow, 1996; Stokes et al., 1999).  Dopamine can 
have many fates within the synapse, including release into the synaptic cleft, reuptake 
into the presynaptic terminal for recycling, degradation by enzyme-catalyzed oxidation, 
non-enzymatic auto-oxidation, and deposition into neuromelanin, the pigmented structure 
for which the SN is named.  The enzyme- or metal-catalyzed oxidation of dopamine can 
generate cytotoxic quinones, hydrogen peroxide, and oxyradicals (Graham 1978), raising 
important questions as to the role of dopamine in the degeneration of dopaminergic 
neurons.  
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1.4.1 Dopamine synthesis and metabolism 
Dopamine is synthesized in the cytosol from the amino acid L-tyrosine.  The first 
step in this reaction is rate-limiting; the enzyme tyrosine hydroxylase (TH) catalyzes the 
conversion of L-tyrosine to L-DOPA using molecular oxygen and tetrahydrobiopterin as 
cofactors.  L-DOPA is converted to dopamine by aromatic amino acid decarboxylase 
(AADC), generating carbon dioxide as a byproduct.  The end-product, dopamine, serves 
to regulate its own levels through feedback inhibition of TH (Nagatsu et al., 1964; Levitt 
et al., 1965).  Two residues, Arg-37 and Arg-38, in the N-terminal regulatory domain of 
TH are required for this inhibition.  Mutation of these residues to Glu-37, Glu-38 
significantly increases the catalytic activity of TH (Nakashima et al., 2002), which was 
exploited in the current work to achieve unregulated elevation of dopamine levels.  
Upon synthesis, dopamine is immediately packaged into synaptic vesicles by the 
vesicular monoamine transporter 2 (VMAT2) (Erickson et al., 1992).  VMAT2 is coupled 
to a vesicular ATPase that generates a proton gradient, resulting in the pH within synaptic 
vesicles of ~5.6 (Johnson and Scarpa, 1976; Casey et al., 1977).  The acidic environment 
facilitates neurotransmitter packaging, as two protons are exchanged for each molecule of 
dopamine (Knoth et al., 1981), and also prevents dopamine from becoming oxidized.  
Upon stimulation by an action potential, synaptic vesicles loaded with neurotransmitter 
fuse with the presynaptic membrane and dopamine is released into the synaptic cleft.  
Dopamine can then bind to D1- or D2-type postsynaptic receptors, as well as D2-type 
presynaptic autoreceptors, and get recycled back into the presynaptic neuron by the 
dopamine transporter (DAT) (Segura-Aguilar et al., 2014; Surmeier et al., 2014; Ford, 
2014). 
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Dopamine degradation is achieved by enzyme-catalyzed oxidation, which 
necessarily produces potentially toxic aldehydes and peroxides.  Both in the nerve 
terminal and extracellularly, monoamine oxidase (MAO) catalyzes the oxidative 
deamination of dopamine into 3,4-dihydroxyphenylacetaldehyde (DOPAL), generating 
hydrogen peroxide as a byproduct.  DOPAL, a recognized neurotoxin (Burke et al., 2003; 
Goldstein et al., 2013), is further oxidized to the non-toxic 3,4-dihydroxyphenylacetate 
(DOPAC) by aldehyde dehydrogenase.  Extracellularly, DOPAC is converted to 
homovanillic acid (HVA) by catechol-O-methyl transferase (COMT).  COMT can also 
act directly on dopamine to generate 3-methoxytyramine, which can in turn be 
metabolized to HVA by extracellular MAO and aldehyde dehydrogenase (Segura-Aguilar 
et al., 2014).  
 
1.4.2 Dopamine auto-oxidation and antioxidant defenses 
 Dopamine that is not degraded or 
packaged into synaptic vesicles is able to 
auto-oxidize in the cytosol, generating 
electron-deficient quinones and reactive 
oxygen species (Graham 1978; Smythies et 
al., 1998; Sulzer et al., 2000).  Dopamine 
contains a catechol moiety (vicinal hydroxyls 
on an aromatic ring) which can readily 
donate two electrons to form dopamine-o-
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quinone (see Figure 1.3).  If the electron acceptor is molecular oxygen, this generates 
superoxide anion radicals.  Dopamine-o-quinone can undergo deprotonation of the amine 
group and cyclization to generate leukoaminochrome, which can further oxidize to form 
the quinone, aminochrome.  The rearrangement of aminochrome to 5,6-dihydroxyindole 
is followed by oxidation to 5,6-indolequinone and polymerization to form neuromelanin. 
Neuromelanin is an insoluble, granular structure that is thought to be a protective 
mechanism for the sequestration of reactive derivatives of oxidized dopamine (Sulzer et 
al., 2000).  However, the observation that pigmented midbrain neurons are preferentially 
lost in PD (Hirsch et al., 1988) suggests that neuromelanin and/or its precursors could 
directly contribute to neuronal injury. 
In addition to being deposited in neuromelanin, the products of dopamine 
oxidation can be cleared by antioxidant enzymes and oxidant scavengers.  Superoxide 
radicals are converted to hydrogen peroxide and molecular oxygen by superoxide 
dismutases (SODs).  SODs are metalloenzymes localized to the cytoplasm (copper- and 
zinc-containing SOD) and mitochondrial matrix (manganese-containing SOD) (McCord 
and Fridovich, 1969).  Glutathione peroxidase removes hydrogen peroxide by oxidizing 
glutathione, and reduced glutathione is restored by glutathione reductase.  Alternatively, 
hydrogen peroxide can be broken down to molecular oxygen and water by catalase (Fahn 
and Cohen, 1992).  There is some evidence that dopamine quinones may be removed via 
conjugation to glutathione, either spontaneously or catalyzed by glutathione S-
transferases (Baez et al., 1997).  Conjugation of dopamine-o-quinone to glutathione 
forms 5-S-glutathionyl dopamine, which is degraded to 5-S-cysteinyldopamine.  The 
latter product has been detected in human basal ganglia (Rosengren et al., 1985).   
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1.4.3 The role of dopamine in oxidative stress  
 Due to the propensity of dopamine to auto-oxidize and its normal clearance via 
oxidative metabolism, neurons in the SN are thought to be at high risk of oxidative stress.  
Oxidative stress occurs when the concentration of oxidants exceeds the antioxidant 
buffering capacity of the cell.  Oxidants such as dopamine quinones, hydrogen peroxide, 
and oxyradicals can damage all major classes of macromolecules, potentially leading to 
cellular dysfunction and death (Fahn and Cohen, 1992; Jenner and Olanow, 1996; Stokes 
et al., 1999).  Several studies have identified markers of oxidative stress in postmortem 
PD brain tissue.  In the SN, polyunsaturated fatty acid content was found to be reduced 
compared with other brain regions and tissue from controls, while products of lipid 
peroxidation including malondialdehyde as well as 4-hydroxynonanol protein adducts 
were increased (Dexter et al., 1989a; Yoritaka et al., 1996).  Lewy bodies exhibit robust 
immunoreactivity for protein nitration, including specifically nitrated α-synuclein (Good 
et al., 1998; Giasson et al., 2000), and oxidatively modified nucleic acids are present in 
SN neurons as well (Zhang et al., 1999).  
The SN contains high concentrations of iron (Hallgren and Sourander, 1958), 
putting this region at risk for both iron-catalyzed dopamine oxidation and production of 
highly toxic hydroxyl radicals.  Ferric iron (Fe3+) can catalyze the formation of dopamine 
quinones and, once it is reduced to ferrous iron (Fe2+), can react with hydrogen peroxide 
via the Fenton reaction to produce hydroxyl radical.  In the presence of superoxide 
radical, Fe2+ can be continually regenerated from Fe3+ in a dangerous cycle of Haber-
Weiss type reactions (Fahn and Cohen, 1992).  PD patients have increased total iron and 
specifically Fe3+ in SN relative to healthy controls, whereas glutathione levels are 
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decreased (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989b; 1991).  These 
alterations are consistent with increased potential for iron-catalyzed oxidation reactions, 
coupled with a reduced capacity of the antioxidant response.  
Dopamine quinones are potentially neurotoxic via the covalent adduction to 
cysteine sulfhydryl groups.  Cysteines are often located in the active site of proteins, and 
adduction may therefore irreversibly impair protein function (Sulzer et al., 2000).  
Catecholamine cysteinyl adducts are selectively increased in the SN of PD patients, 
though it is unknown if this is due to L-DOPA therapy (Spencer et al., 1998).  The 
protein targets of dopamine modification have been explored in various model systems 
(Segura-Aguilar et al., 2014).  Proteomic analysis was performed on isolated rat brain 
mitochondria and SH-SY5Y cells that were exposed to radiolabeled dopamine or 
dopamine quinone.  A subset of mitochondrial proteins as well as the PD-linked proteins 
DJ-1 and UCH-L1 were found to be covalently modified by dopamine (Van Laar et al., 
2009).  This is consistent with evidence that dopamine quinone alters mitochondrial 
function and induces swelling, effects which are inhibited by the addition of glutathione 
(Berman and Hastings, 1999).  PD-associated parkin was found to be modified by 
catechols in human SN, and modification of parkin by dopamine in neuronal cell lines 
caused its functional inactivation (LaVoie et al., 2005).  Dopamine quinone has also been 
reported to covalently modify and inhibit the function of TH (Xu et al., 1998; Kuhn et al., 
1999) and DAT (Berman et al., 1996; Whitehead et al., 2001). 
 Toxin-based models of PD lend support for oxidative stress playing a role in 
dopaminergic cell death.  The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) induces parkinsonism via its active metabolite, 1-methyl-4-phenylpyridinium 
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(MPP+) (Dauer and Przedborski, 2003), an effect which was first observed in drug users 
who inadvertently synthesized MPTP (Davis et al., 1979; Langston et al., 1983).  
Postmortem studies in these individuals as well as MPTP administration in monkeys and 
mice has revealed nigrostriatal degeneration and depletion of striatal dopamine, 
consistent with PD.  Lewy body pathology has not been consistently observed, however 
(Davis et al., 1979; Forno et al., 1993; Langston et al., 1999; Moratalla et al., 1992; 
Muthane et al., 1994; Seniuk et al., 1990; Varastet et al., 1994).  MPP+ is selectively 
taken up by dopaminergic neurons through DAT (Javitch et al., 1985), and acts to inhibit 
mitochondrial complex I activity (Nicklas et al., 1987).  This can lead to production of 
superoxide and other reactive oxygen species, and consequently oxidative stress 
(Hasegawa et al., 1990; 1997).  The insecticide rotenone also causes dopamine neuron 
loss by inhibiting complex I (Betarbet et al., 2000), and the herbicide paraquat, which is 
structurally related to MPP+, increases levels of superoxide (Day et al., 1999).  Both 
rotenone and paraquat are able to initiate formation of Lewy body-like α-synuclein 
inclusions in rodents (Dauer and Przedborski, 2003).  Furthermore, there is evidence for 
increased risk of PD with herbicide/pesticide exposure (Tanner, 1992).   
 
1.4.4 Animal models of dopamine toxicity 
 A limited number of studies have investigated whether dopamine is toxic in vivo.  
Intrastriatal injection of high concentrations of dopamine (up to 1 μmol) in rats resulted 
in loss of dopaminergic nerve terminals and formation of protein cysteinyl-dopamine 
adducts within one week.  The size of the lesion correlated with the concentration of 
dopamine injected, and co-administration of glutathione or ascorbate both mitigated 
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toxicity and decreased adduct formation (Filloux and Townsend, 1993; Hastings et al., 
1996; Rabinovic et al., 2000).  Similarly, rats injected with aminochrome into the SN 
showed evidence of neurodegeneration and motor impairment (Díaz-Véliz et al., 2002; 
Touchette et al., 2016). 
In addition to direct administration of dopamine or its oxidized derivatives, 
pharmacological and genetic approaches have been taken to manipulate endogenous 
dopamine handling and assess the effects on the nigrostriatal system.  While a complete 
knockout of VMAT2 is lethal (Wang et al., 1997), transgenic mice expressing 5% of 
normal VMAT2 levels in order to increase cytosolic dopamine did not have SN cell loss 
(Colebrooke et al., 2006).  In a different strain of the same mice, a mild, progressive 
degenerative phenotype was reported in combination with elevated levels of cysteinyl-
catechols (Caudle et al., 2007).  Amphetamines are highly toxic to dopaminergic nerve 
terminals, which is thought to be mediated at least in part by the redistribution of 
dopamine from synaptic vesicles into the cytosol (Sulzer et al., 1995; LaVoie and 
Hastings, 1999).  Mice deficient in VMAT2 exhibit greater sensitivity to meth-
amphetamine, consistent with exacerbated toxicity of cytosolic dopamine (Fumagalli et 
al., 1999; Guillot et al., 2008).  Conversely, overexpression of VMAT2 is protective 
against methamphetamine-induced damage (Lohr et al., 2015).  Reserpine, another 
inhibitor of vesicular dopamine storage, is not neurotoxic, possibly since its effects are 
transient (Tieu, 2011).  The elevation of cytosolic dopamine by overexpression of DAT 
in SN neurons (Masoud et al., 2015) or ectopic DAT expression in striatal neurons (Chen 
et al., 2008a) has resulted in neurodegeneration and oxidative stress.  Collectively, these 
studies emphasize the potential role of dopamine in PD etiology. 
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1.5 The interaction of dopamine and α-synuclein 
1.5.1 Structural characterization 
In 2001, Lansbury and colleagues conducted a screen for compounds that inhibit 
α-synuclein fibrillization in vitro.  Of the 15 candidates identified as potent modifiers of 
aggregation, 14 were catecholamines.  Dopamine was found to kinetically arrest soluble 
α-synuclein oligomers, and this effect was blocked by antioxidants (Conway et al., 2001).  
Subsequent studies have confirmed that dopamine stabilizes oligomer species in vitro 
even at substoichiometric concentrations, and oxidation of dopamine but not α-synuclein 
is required (Li et al., 2004; 2005a; Norris et al., 2005; Cappai et al., 2005; Follmer et al., 
2007; Herrera et al., 2008; Pham et al., 2009; Bisaglia et al., 2010; Mazzulli et al., 2016).  
Consistent with these findings, elevating dopamine levels in SH-SY5Y cells expressing 
A53T α-synuclein reduced the number of cells containing insoluble aggregates and 
increased levels of soluble, high molecular weight oligomers.  Moreover, the appearance 
of these species was prevented by antioxidant treatment (Mazzulli et al., 2006; 2007).   
The requirement of dopamine oxidation suggests that α-synuclein may interact 
with dopamine quinones.  Indeed, aminochrome was found to effectively inhibit α-
synuclein fibril formation (Li et al., 2004; Norris et al., 2005), and incubation of 
dopamine with α-synuclein results in quinone-associated protein (Li et al., 2005a; 
Mazzulli et al., 2016).  Interestingly, α-synuclein does not contain cysteine residues and 
therefore cannot form cysteinyl adducts.  Mutating other reactive residues that could 
become covalently modified by dopamine does not have an effect, suggesting that the 
interaction is non-covalent.  Consistent with this, dopamine-mediated inhibition of α-
synuclein fibrillization is reversible (Norris et al., 2005), and does not generate 
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appreciable dopamine-protein adduct as measured by mass spectrometry and 
radiolabeling (Li et al., 2004; Norris et al., 2005; Pham et al., 2009; Bisaglia et al., 2010).  
The sites of interaction between dopamine and α-synuclein likely include residue E83 
and the 125-YEMPS-129 motif in the C-terminus, since mutation or deletion of these 
sites restores the ability of α-synuclein to fibrillize in the presence of dopamine (Norris et 
al., 2005; Herrera et al., 2008).  The dopamine-mediated increase in oligomeric species 
observed in SH-SY5Y cells is also prevented by expression of α-synuclein lacking the 
125-YEMPS-129 domain (Mazzulli et al., 2007). 
Dopamine-stabilized α-synuclein oligomers have been extensively characterized 
using a combination of biochemical and imaging techniques.  Recombinant oligomers 
generated in the presence of dopamine appear spherical or dot-like by electron 
microscopy and atomic force microscopy, and both N- and C-termini of α-synuclein are 
exposed (Cappai et al., 2005; Li et al., 2005a; Norris et al., 2005; Follmer et al., 2007).  
These species migrate as high molecular weight bands on SDS-PAGE, indicating that 
they are SDS- and heat-stable.  Further analysis by size exclusion chromatography 
reveals a range of elution times, corresponding to heterogeneous oligomer conformations 
(Conway et al., 2001; Cappai et al., 2005; Li et al., 2005a; Pham et al., 2009; Bisaglia et 
al., 2010; Mazzulli et al., 2016).  By circular dichroism, dopamine-incubated α-synuclein 
is largely composed of random coil structure, consistent with ‘off-pathway’ species that 
do not progress to form β-sheet rich fibrils (Li et al., 2004; Cappai et al., 2005; Norris et 
al., 2005; Pham et al., 2009; Bisaglia et al., 2010).  Collectively, these studies indicate 
that oxidized dopamine potently modifies α-synuclein aggregation, resulting in diverse 
soluble oligomeric conformers. 
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1.5.2 Functional characterization 
Growing evidence suggests that α-synuclein oligomers are neurotoxic species.  
Viral expression of artificial α-synuclein variants with enhanced oligomerization in the 
rat SN resulted in the selective loss of dopaminergic neurons (Winner et al., 2011).  
Similarly, artificial mutants with impaired β-sheet structure and increased propensity to 
form oligomers caused degeneration of dopaminergic nerve terminals when expressed in 
worms and overt dopaminergic cell loss in flies (Karpinar et al., 2009).  In another study, 
oligomer extracts from A53T α-synuclein transgenic mice were found to be toxic when 
applied to primary cortical cultures, while extracts immunodepleted of α-synuclein were 
not (Tsika et al., 2010).  Recombinant α-synuclein oligomers generated in vitro have also 
been shown to be neurotoxic in culture (Danzer et al., 2007), and oligomer formation is 
accelerated by the A53T and A30P familial PD mutations (Conway et al., 2000b).  
Moreover, soluble high molecular weight oligomers have been extracted from human 
brain tissue and are increased in PD patients (Sharon et al., 2003).  
The toxicity of dopamine-induced α-synuclein oligomers is largely unexplored.  
Evidence from neuronal cultures and cell-free assays suggests that these species are able 
to inhibit their own degradation as well as that of other substrates by chaperone-mediated 
autophagy (Martinez-Vicente et al., 2008).  While there is no evidence that increasing 
dopamine in SH-SY5Y cultures produces toxic α-synuclein oligomers (Mazzulli et al., 
2006; Yamakawa et al., 2010), exogenous application of recombinant dopamine-
stabilized oligomers has been reported to reduce viability and neurotransmitter release in 
PC12 cells (Li et al., 2005a; Choi et al., 2013).  A30P α-synuclein oligomers generated in 
the presence of dopamine reduced neurite number and length in primary 
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mesencephalic and cortical cultures (Follmer et al., 2007).  In addition, the toxicity of 
endogenous cytosolic dopamine in cultured fetal human dopaminergic neurons was 
linked to the accumulation of soluble α-synuclein protein complexes (Xu et al., 2002).  
 
1.6 Rationale and objectives 
A major stumbling block in the development of effective treatments for PD has 
been the inadequate understanding of two defining disease features: the progressive death 
of dopaminergic neurons in the SN, and the widespread formation of α-synuclein 
inclusions.  A longstanding hypothesis suggests that dopamine contributes to disease 
pathogenesis through the generation of cytotoxic quinones and other electrophiles 
(Graham, 1978), yet dopamine toxicity has not been extensively studied in animal 
models.  Oxidized dopamine has been shown to stabilize potentially toxic α-synuclein 
oligomers in cultured cells and cell-free systems (Conway et al., 2001; Norris et al., 2005; 
Mazzulli et al., 2006; 2007).  However, it remains unknown if dopamine is able to 
modify α-synuclein oligomerization in vivo and whether the resultant species are capable 
of driving neurodegeneration.  
To explore the possibility that dopamine and α-synuclein interact in vivo, we 
manipulated both endogenous dopamine levels and α-synuclein expression in mice 
(Chapter 2).  Using A53T human α-synuclein transgenic mice (Giasson et al., 2002) and a 
novel lentiviral approach to enhance dopamine synthesis, we aimed to accomplish three 
major goals: (1) to test if sustained elevation of dopamine levels induces nigrostriatal 
degeneration, (2) to determine if dopamine toxicity is dependent on α-synuclein 
expression, and (3) to test if dopamine modifies α-synuclein aggregation in vivo 
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resulting in potentially toxic species.  We found that both elevated dopamine levels and 
α-synuclein expression are required for neurodegeneration of the SN, and that dopamine 
promotes conformationally and functionally modified α-synuclein oligomer species in 
vivo.  In addition, we found that dopamine-stabilized recombinant α-synuclein oligomers 
are structurally similar to mouse-derived oligomers and are toxic to primary neuronal 
cultures.  These findings reveal a synergistic interaction between dopamine and α-
synuclein that may account for the vulnerability of dopaminergic neurons in disease.   
In Chapter 3, we review what is known regarding α-synuclein physiological 
functions and native conformations.  A model for the transition from native α-synuclein 
conformers to aggregation-competent species is proposed.   
Finally, Chapter 4 provides a summary of our findings, their significance within 
the broader scientific understanding, and clinical implications.  Important questions that 
remain following this work, as well as future studies that may address these questions, are 
highlighted. 
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2.1  Abstract 
Parkinson’s disease is defined by the loss of dopamine producing neurons in the 
substantia nigra (SN) and an abundance of Lewy body inclusions comprised of 
aggregated α-synuclein.  To date, efforts to explain the selective vulnerability of 
dopamine neurons have been hindered by the lack of overt dopaminergic cell death in 
transgenic mice overexpressing α-synuclein.  To address this issue, dopamine levels were 
manipulated in addition to α-synuclein expression, since the oxidative properties of 
dopamine have long been suspected to contribute to dopaminergic cell death.  SN-
targeted expression of mutant tyrosine hydroxylase, which is insensitive to feedback 
inhibition by dopamine, increased the steady-state levels of dopamine without damaging 
dopaminergic cells in non-transgenic mice.  In contrast, raising dopamine levels in mice 
expressing human A53T mutant α-synuclein induced progressive nigrostriatal 
degeneration and a reduction of locomotion.  A possible mechanism for this converging 
action is dopamine-mediated stabilization of α-synuclein oligomers, which occurs in cell-
free and culture systems but has not been tested in vivo.  Elevation of dopamine in A53T 
transgenic mice increased the total levels of soluble α-synuclein oligomers and resulted in 
conformationally and functionally modified species.  Moreover, dopamine-induced        
α-synuclein oligomers generated in vitro decreased viability in primary neuronal cultures.  
The data demonstrate that SN degeneration is dependent on both dopamine levels and    
α-synuclein, suggesting a unique interaction by which two cardinal features of 
Parkinson’s disease, dopaminergic cell death and α-synuclein aggregation, are linked to 
account for the vulnerability of this neuronal population. 
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2.2 Introduction 
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder that is 
principally defined by the motor symptoms of resting tremor, rigidity, and bradykinesia.  
These symptoms occur primarily as a result of the progressive loss of dopaminergic 
neurons in the substantia nigra pars compacta (SN), which depletes dopamine at 
nigrostriatal synapses (Parkinson, 1817; Hassler, 1938; Ehringer and Hornykiewicz, 
1960).  A longstanding hypothesis to explain the vulnerability of this cell population 
states that dopamine induces neuronal injury via oxidative stress.  The enzyme- or metal-
catalyzed oxidation of dopamine generates electron-deficient quinones and reactive 
oxygen species that can induce cellular dysfunction (Graham, 1978; Fahn and Cohen, 
1992; Jenner and Olanow, 1996; Stokes et al., 1999).  The SN in PD patients is reported 
to harbor oxidatively modified proteins, lipids, and nucleic acids (Dexter et al., 1989a; 
Yoritaka et al., 1996; Zhang et al., 1999; Giasson et al., 2000).  Efforts to study the 
effects of dysregulated dopamine in animal models have included ectopic dopamine 
administration or increased cytosolic dopamine by suppression of VMAT2 expression 
(Hastings et al., 1996; Colebrooke et al., 2006; Caudle et al., 2007).  
More recently, α-synuclein has emerged as a critical player in PD pathogenesis.  
Disturbances in α-synuclein protein folding or expression level, i.e. through mutations or 
extra copies of the α-synuclein gene, are known causes of PD (Polymeropoulos et al., 
1997; Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et al., 2004; Zarranz et 
al., 2004; Proukakis et al., 2013; Lesage et al., 2013; Pasanen et al., 2014; Ferese et al. 
2015).  In both familial and sporadic cases, aggregated α-synuclein is present within 
Lewy bodies and Lewy neurites, which are the hallmark pathological lesions of the 
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disease (Spillantini et al., 1997; Baba et al., 1998).  α-Synuclein is a small highly 
conserved protein (140 residues) that is abundantly expressed in the nervous system 
primarily at presynaptic terminals (Maroteaux et al., 1988; Jakes et al., 1994; Iwai et al., 
1995).  The precise physiological functions of α-synuclein remain unclear, though it is 
thought to play diverse roles in synaptic maintenance and plasticity, neurotransmitter 
release and homeostasis, and the regulation of synaptic vesicle pools (George et al., 1995; 
Withers et al., 1997; Abeliovich et al., 2000; Murphy et al., 2000; Cabin et al., 2002; 
Yavich et al., 2004; Chandra et al., 2005; Burré et al., 2010; Nemani et al., 2010).  In 
disease, α-synuclein assembles into β-sheet rich amyloid-like fibrils, generating several 
intermediate oligomeric species of unknown toxicity (Ross and Poirier, 2005).   
Intriguingly, α-synuclein oligomers are kinetically stabilized by oxidized 
dopamine and other catecholamines in vitro (Conway et al., 2001; Norris et al., 2005), 
providing a possible link between dopamine- and α-synuclein-mediated toxicities.  
Extensive evidence from cultured cells and cell-free systems indicates that dopamine 
potently and substoichiometrically inhibits the fibrillization of α-synuclein, resulting in 
the kinetic arrest of soluble oligomer species.  Dopamine oxidation is required for 
oligomer stabilization, suggesting α-synuclein interacts with dopamine-quinone and/or 
other oxidation products.  The interaction is non-covalent, reversible, and dependent on 
residues E83 and 125-YEMPS-129 motif in the C-terminus of α-synuclein (Conway et 
al., 2001; Norris et al., 2005; Cappai et al., 2005; Mazzulli et al., 2006; 2007; Follmer et 
al., 2007; Herrera et al., 2008).  The toxicity of these oligomers is largely unexplored, 
though in vitro dopamine-incubated α-synuclein is reported to interfere with and resist 
degradation by chaperone-mediated autophagy (Martinez-Vicente et al., 
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2008), and to inhibit SNARE complex formation and neurotransmitter release (Choi et 
al., 2013).  Importantly, it is unknown if dopamine is able to modify α-synuclein 
oligomerization    in vivo and whether the resultant species are capable of driving 
neurodegeneration.  These are the critical questions we aimed to answer in this study. 
 
2.3 Results 
2.3.1 Expression of TH-RREE elevates dopamine levels and causes hyperactivity in 
NonTg mice 
To increase dopamine levels in vivo, we used a lentiviral vector carrying the 
cDNA of human tyrosine hydroxylase (TH).  TH is the rate-limiting enzyme in dopamine 
biosynthesis converting tyrosine to L-DOPA, which is then metabolized by aromatic 
amino acid decarboxylase to generate dopamine.  A mutated TH enzyme that has Arg37-
Arg38 replaced by Glu37-Glu38 (TH-RREE) is insensitive to feedback inhibition by 
dopamine and was used to achieve increased catalytic activity of TH (Nakashima et al., 
2002; Mazzulli et al., 2006; 2007).  The function of the vector was first tested on human 
neuroblastoma SH-SY5Y cells.  This cell line has undetectable levels of endogenous TH, 
despite the expression of other enzymes required for synthesis and processing of 
dopamine.  The cells were transduced after 5 days of differentiation with 20 µM retinoic 
acid and TH expression was confirmed by western blot and immunocytochemistry 
compared with empty vector (CtrlVect)-transduced controls (Figure 2.S1a-c).  The      
TH-RREE transduced cells had measurable intracellular levels of L-DOPA, dopamine, 
and DOPAC in the range of 25-200 fm/μg, whereas catecholamines were not detected in 
CtrlVect-transduced cells (Figure 2.S1d). 
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We performed bilateral injections of TH-RREE vector into the SN of aged (10 
month old) NonTg mice.  This age was selected because the mice expressing A53T 
mutant human α-synuclein are asymptomatic and do not exhibit the well-known motor 
phenotype derived from spinal cord degeneration (Giasson et al., 2002).  The typical age 
of onset of this phenotype in our colony is approximately 18 months.  At 5 months post-
injection (mpi), TH expression was increased in both SN and striatum in NonTg          
TH-RREE   mice  compared   to   age-matched  NonTg  CtrlVect  mice   (Figure  2.1a-b).   
 
Figure 2.1: Increased dopamine levels in the striatum of NonTg mice results in 
hyperactivity.  (a) TH protein levels were increased in the striatum of TH-RREE vector injected 
mice relative to empty vector-injected controls (CtrlVect) at 5 mpi.  Densitometric analysis was 
conducted by normalizing TH to the GAPDH loading control.  The data are presented as mean ± 
s.e.m.  (n = 3; two-tailed unpaired Student’s t test).  (b) Increased TH expression was confirmed 
by immunohistochemistry in the SN (left panels) and striatum (right panels).  Scale bar, 200 μm.  
(c) TH overexpression significantly increased the steady state concentrations of striatal 
catecholamines L-DOPA and dopamine (DA), but did not alter DOPAC or 5-HT.  The data are 
presented as mean ± s.e.m.  (n = 4 except DOPAC n = 5 for CtrlVect, and 5-HT n =3 for TH-
RREE; two-tailed unpaired Student’s t test).  (d) TH-RREE injected NonTg mice exhibited 
greater locomotion as measured by open field activity.  The data are presented as mean ± s.e.m.  
(n = 5; two-tailed unpaired Student’s t test).  (e) There was no change in rotarod performance 
between the injection groups.  The data are presented as mean ± s.e.m.  (n = 3; two-tailed 
unpaired Student’s t test).  *P < 0.05. 
 37
TH-RREE significantly elevated striatal concentrations of L-DOPA and dopamine by 36 
and 52%, respectively, while DOPAC was not affected.  Importantly, 5-HT levels did not 
change, indicating a specific effect on the catecholamine neurotransmitter system (Figure 
2.1c).  Consistent with elevated striatal dopamine, NonTg TH-RREE mice exhibited 
hyperactivity in open field testing compared with NonTg CtrlVect mice (Figure 2.1d).  
There was no difference in rotarod performance between the NonTg injection groups 
(Figure 2.1e).  These data indicate that the TH-RREE vector is able to significantly 
enhance dopamine levels fully 5 months following injection. 
 
2.3.2 Dopamine-induced neurodegeneration and motor deficit is dependent on                
α-synuclein expression 
Bilateral injection of the TH-RREE vector into the SN of 10 month old A53T 
mutant α-synuclein mice also achieved TH overexpression (Figure 2.S2).  However, in 
contrast to NonTg mice, A53T TH-RREE mice exhibited striatal degeneration and 
neuronal loss in the SN at 5 mpi.  To avoid the detection of vector-encoded TH, we used 
another marker of dopaminergic neurons, VMAT2, to evaluate neuronal loss.  A53T   
TH-RREE mice had fewer VMAT2 positive cells in the SN compared with all other 
injection groups (Figure 2.2a).  We quantified the loss of neurons using unbiased 
stereological counting of Nissl cells, which revealed a significant 25% reduction in A53T 
TH-RREE mice compared to controls (Figure 2.2b).  The number of neurons quantified 
in age-matched A53T CtrlVect as well as NonTg CtrlVect and NonTg TH-RREE mice 
was typical for the mouse SN (Tieu et al., 2003), indicating that neurodegeneration had 
not occurred in these mice (Figure 2.2b). 
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Figure 2.2: Dopamine-induced neurodegeneration of the SN is dependent on α-synuclein.  
(a) At 5 mpi, fewer VMAT2 positive cells were present in the SN of A53T TH-RREE mice 
(arrows) compared with all other injection groups.  Scale bar, 100 μm.  (b) Unbiased stereological 
counting of Nissl-positive neurons in the SN revealed a significant 25% loss of cells in A53T TH-
RREE mice.  The data are presented as mean ± s.e.m.  (n = 3 except n = 4 for A53T TH-RREE; 
one-way ANOVA with Tukey’s correction for multiple comparisons).  (c-d) Histological analysis 
of VMAT2 staining in the striatum, with subtraction of background staining in the cortex, 
indicated severe dopaminergic denervation in A53T TH-RREE mice.  Scale bar, 200 μm.  The 
data are presented as mean ± s.e.m.  (n = 3; one-way ANOVA with Tukey’s correction for 
multiple comparisons).  (e-f) Striatal DAT levels normalized to the actin loading control were 
increased in NonTg TH-RREE mice relative to NonTg CtrlVect, whereas DAT levels were 
decreased in A53T TH-RREE mice as compared to A53T CtrlVect.  The data are presented as 
mean ± s.e.m.  (n = 3 except n = 4 for NonTg CtrlVect; one-way ANOVA with Tukey’s 
correction for multiple comparisons).  *P < 0.05, **P < 0.01.   
 
The degeneration of cell bodies was accompanied by a significant 62% decrease 
in VMAT2 staining in the striatum of A53T TH-RREE mice, demonstrating a severe loss 
of dopaminergic nerve terminals (Figure 2.2c-d).  Denervation of the striatum was further 
corroborated by quantification of DAT levels, which revealed a significant 55% decline 
in A53T TH-RREE mice compared with A53T CtrlVect.  In contrast, DAT levels 
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were two-fold higher in NonTg TH-RREE as compared to NonTg CtrlVect mice (Figure 
2.2e-f).  DAT upregulation may serve to compensate for increased dopamine levels, and 
may not be apparent in A53T TH-RREE mice due to the substantial loss of dopaminergic 
terminals.  The injury in A53T mice appears to be primarily presynaptic in that levels of 
D1 and D2 receptors remained unchanged (Figure 2.S3a-c).  Levels of dopamine- and 
cAMP-regulated phosphoprotein-32 (DARPP-32), which serves as an important signaling 
molecule in spiny projection neurons, were also unaffected (Figure 2.S3a,d).   
To further investigate the degenerative phenotype in A53T TH-RREE mice and 
whether it is progressive, the total number of SN neurons was quantified at the earlier 
timepoint of 2.5 mpi.  No difference was observed between A53T CtrlVect and TH-
RREE mice, indicating that cell loss had not yet occurred (Figure 2.3a).  Despite the 
maintenace of neuronal cell bodies, striatal VMAT2 levels revealed a 25% decrease in 
nerve terminal density by this timepoint, suggesting that degeneration had begun at 
dopaminergic synapses (Figure 2.3b).  DAT levels were instead found to be increased in 
A53T TH-RREE mice relative to CtrlVect mice at 2.5 mpi (Figure 2.3c), similar to 
NonTg TH-RREE mice at 5 mpi (Figure 2.2e-f).  Consistent with a compensatory 
increase in DAT, dopamine levels at 2.5 mpi were significantly elevated by 71% in A53T 
TH-RREE mice compared with age-matched A53T CtrlVect mice (Figure 2.3d).   
Following the initial increase in dopamine, however, A53T TH-RREE mice 
subsequently exhibited a 37% drop in striatal dopamine content between 2.5 and 5 mpi. 
A53T CtrlVect mice showed no change in dopamine during the same time period (Figure 
2.3d).  The reduction in dopamine levels cannot be explained by increased conversion to 
DOPAC since  levels of this metabolite  remained   unchanged  from  2.5 to 5  mpi   
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Figure 2.3: Development of the neurodegenerative phenotype in A53T TH-RREE mice 
ultimately leading to locomotor deficit.  (a) At the early timepoint of 2.5 mpi, A53T TH-RREE 
mice did not yet exhibit loss of neuronal cell bodies in the SN.  The data are presented as mean ± 
s.e.m.  (n = 4 except n = 3 for TH-RREE; two-tailed unpaired Student’s t test).  (b) VMAT2 
staining in the striatum revealed a modest loss of terminals suggesting that dopaminergic 
synapses had degenerated prior to overt cell death.  Scale bar, 200 μm.  The data are presented as 
mean ± s.e.m.  (n = 4; two-tailed unpaired Student’s t test).  (c) DAT levels in the striatum of 
A53T TH-RREE mice were instead found to be increased at 2.5 mpi.  The data are presented as 
mean ± s.e.m.  (n = 3; two-tailed unpaired Student’s t test).  (d) A53T TH-RREE mice exhibited 
an elevation of dopamine (DA) levels only transiently, with an initial increase of 71% at 2.5 mpi 
compared with age-matched A53T CtrlVect mice.  Subsequently, however, A53T TH-RREE 
mice underwent a significant 37% drop in striatal dopamine between 2.5 and 5 mpi, which was 
not observed in A53T CtrlVect mice.  The data are presented as mean ± s.e.m.  (n = 3 except n = 
5 for TH-RREE 2.5 mpi; one-way ANOVA with Tukey’s correction for multiple comparisons).  
(e) Consistent with a late-onset depletion of dopamine in the striatum, from 2.5 to 5 mpi A53T 
TH-RREE mice developed a reduction in locomotor activity that was not observed in CtrlVect 
mice.  The data are presented as mean ± s.e.m.  (n = 3; one-way ANOVA with Tukey’s correction 
for multiple comparisons).  (f) The motor deficit in A53T TH-RREE mice was not severe enough 
to affect coordination or balance, as rotarod performance remained intact.  The data are presented 
as mean ± s.e.m.  (n = 4 except n = 3 for TH-RREE 2.5 mpi and CtrlVect 5 mpi; one-way 
ANOVA with Tukey’s correction for multiple comparisons).  *P < 0.05, **P < 0.01. 
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(Figure 2.S4a).  We also did not detect an increase in dopamine-protein adducts by near 
infrared fluorescence (Figure 2.S4b-c).  Rather, the loss of dopamine is likely due to the 
ongoing nigrostriatal degeneration documented in these mice.  Concomitant with the 
decrease in dopamine levels, A53T TH-RREE mice exhibited a significant impairment in 
ambulatory activity that was not apparent at 2.5 mpi but emerged by 5 mpi (Figure 2.3e).  
Performance on the rotarod remained intact, suggesting that balance and coordination 
were not disrupted (Figure 2.3f).  Collectively, the results show that dopamine promotes 
the progressive neurodegeneration of dopaminergic neurons and a specific motor deficit 
in mice that express A53T α-synuclein, but not in NonTg mice. 
 
2.3.3 Dopamine modifies α-synuclein oligomer conformations in A53T mice 
The data indicate that increased steady state levels of dopamine result in 
neurotoxicity in an α-synuclein dependent manner.  To investigate possible mechanisms, 
we examined the influence of dopamine on α-synuclein aggregation, and in particular the 
kinetic stabilization of potentially toxic α-synuclein oligomers.  The presence of Lewy 
body-like inclusions in circumscribed regions including the brainstem of aged A53T mice 
has been well documented (Giasson et al., 2002).  α-Synuclein-positive inclusions were 
indeed detected in the brainstem of A53T TH-RREE mice at 5 mpi (age 15 months), 
similar to age-matched A53T CtrlVect mice (Figure 2.S5a).  In contrast, the SN is known 
to remain devoid of inclusions during the lifespan of A53T mice (Giasson et al., 2002).  
Expression of TH-RREE vector did not induce α-synuclein inclusion formation or alter 
levels of detergent-insoluble α-synuclein in the SN at 5 mpi (Figure 2.S5).   
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Examination of detergent-soluble α-synuclein extracted from SN of A53T mice at 
5 mpi revealed significant alterations in the quantities and conformations of α-synuclein 
species as a result of dopamine elevation.  A53T TH-RREE mice had a significant 22% 
reduction in monomeric human α-synuclein compared with A53T CtrlVect mice (Figure 
2.4a-b).  Upon fractionation of the soluble SN extract by native size exclusion 
chromatography (SEC), we detected the presence of various oligomeric α-synuclein 
species of different molecular weights (Figure 2.4c).  Quantification of total oligomeric 
species revealed a significant increase in A53T TH-RREE mice, greater than two-fold 
above A53T CtrlVect mice (Figure 2.4d).  To characterize the oligomers, we used 
multiple α-synuclein antibodies and a combination of SDS-PAGE, immunoelectron 
microscopy, and biochemical assays.  In A53T CtrlVect mice, oligomers had Stokes radii 
of up to 65 Å and ranged in molecular weight from 36 to 80 kD (Figure 2.4c and Figure 
2.S6a-b), consistent with previous observation (Tsika et al., 2010).  However, in addition 
to these low Å species, larger species of up to 122 Å were detected in A53T TH-RREE 
mice.  On 12% SDS-PAGE, these species migrated as dimers, trimers, and high 
molecular weight polymers stable to SDS and heat, consistent with the presence of 
oxidized/crosslinked species (Souza et al., 2000).  The appearance of unique, high Å 
species in A53T TH-RREE mice was observed with multiple α-synuclein antibodies that 
recognize N- or C-terminal epitopes (Figure 2.4c and Figure 2.S6a-b).  Moreover, 
analysis of quinone-associated protein by near-infrared fluorescence revealed that only 
the high Å oligomeric fractions from A53T TH-RREE mice were positive, supporting a 
direct interaction of dopamine and α-synuclein oligomers in these mice (Figure 2.S6c). 
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Figure 2.4: Dopamine induces conformationally distinct α-synuclein oligomers in vivo.  (a-d) 
The SN of A53T TH-RREE and A53T CtrlVect mice at 5 mpi was extracted with 1% Triton and 
the soluble fraction was analyzed by SDS-PAGE (a-b).  The soluble extract was further subjected 
to native size exclusion chromatography and fractions corresponding to 31-38 Å, 41-65 Å, and 
72-122 Å were pooled and analyzed by SDS-PAGE (c-d).  Neural specific enolase (NSE) was 
used as a loading control.  The quantification revealed a decrease in soluble α-synuclein monomer 
and a corresponding increase in α-synuclein oligomers in A53T TH-RREE compared with A53T 
CtrlVect.  The oligomer species in A53T TH-RREE mice were present in higher Å fractions than 
in controls and had a range of molecular weights.  The data are presented as mean ± s.e.m.  
(Monomer, n = 3 for CtrlVect and n = 5 for TH-RREE; Oligomer, n = 3 for CtrlVect and n = 4 
for TH-RREE; two-tailed unpaired Student’s t test).  (e) Immunoelectron microscopy on low (41-
65) and high (72-122) Å fractions using Syn505 (N-terminal) and LB509 (C-terminal) α-
synuclein antibodies, with 10 nm gold-conjugated secondary.  Scale bar, 10 nm.  (f) Pooled 
oligomeric fractions (41-122 Å) from indicated mice were added to aggregation reactions with 
fresh recombinant α-synuclein, and fibril formation was monitored by Thioflavin T (ThioT).  
Prior immunodepletion of α-synuclein from A53T CtrlVect fractions was performed as a control.  
rfu, relative fluorescence units.  The data are presented as mean ± s.e.m.  (n = 3 except n = 4 for 
no seed and immunodepl; repeated measures two-way ANOVA with Tukey’s correction for 
multiple comparisons).  *P < 0.05, **P < 0.01. 
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Further structural analysis of oligomers isolated from high (72-122) or low (41-
65) Å SEC fractions was done by immunoelectron microscopy.  Oligomers typically 
appeared as clusters with >2 gold particles in both high and low Å fractions from A53T 
TH-RREE mice as well as low Å fractions from A53T CtrlVect mice.  The species were 
labeled with α-synuclein antibodies directed at either the N- or C-terminus, indicating 
that both ends were exposed (Figure 2.4e).  Clusters of >2 gold particles were not 
observed in high Å fractions from A53T CtrlVect mice or fractions from A53T TH-
RREE mice that were immunodepleted of α-synuclein prior to imaging.   
Since there is growing evidence for prion-like spreading of α-synuclein pathology 
in disease (Goedert et al., 2010), we investigated if dopamine promotes oligomeric 
species with the capacity to propagate in vivo.  α-Synuclein oligomers extracted from 
A53T TH-RREE and A53T CtrlVect mice (pooled 41-122 Å SEC fractions) were 
monitored in a seeding assay with fresh recombinant α-synuclein in vitro.  In the case of 
CtrlVect mice, oligomers efficiently seeded aggregation relative to the no-seed condition, 
as measured by Thioflavin T (Figure 2.4f).  Importantly, this effect was abolished by 
prior immunodepletion of α-synuclein from the SEC fractions.  In contrast, the same 
fractions from TH-RREE mice were unable to act as seeds (Figure 2.4f), suggesting that 
seeding-competent species were not retained following the interaction of α-synuclein  
with dopamine in vivo.  Collectively, these data indicate that dopamine promotes the 
generation of conformationally and functionally modified α-synuclein oligomeric species 
in the mouse brain.  
 
 
 45
2.3.4 Dopamine-induced α-synuclein oligomers are neurotoxic in primary cultures 
To further establish the link between dopamine-induced oligomers and toxicity, 
we used purified recombinant human wildtype α-synuclein co-incubated with dopamine   
in  vitro.  Consistent with prior reports (Conway et al., 2001; Norris et al., 2005; Cappai 
et al., 2005; Follmer et al., 2007), analysis of amyloid formation with Thioflavin T 
indicated that at equimolar concentrations, dopamine potently inhibited α-synuclein 
fibrillization (Figure 2.5a).  In the absence of dopamine, α-synuclein adopted typical β-
sheet structure indicative of amyloid formation, whereas under conditions with dopamine, 
α-synuclein retained random coil structure (Figure 2.5b).  Sedimentation analysis 
confirmed that dopamine promotes soluble α-synuclein oligomer species that are SDS- 
and heat-stable (Figure 2.5c).  Similar to mouse-derived oligomers, recombinant species 
ranged from 36 to >98 kD and were recognized by both N- and C-terminally directed α-
synuclein antibodies in western blots and by immunoelectron microscopy (Figure 2.5c-d).  
Imaging by electron microscopy revealed clusters of >2 gold particles as observed in 
oligomer fractions from mouse SN (Figure 2.5d and Figure 2.4e).  These findings suggest 
that dopamine-induced oligomers generated in vitro share common epitopes and 
potentially similar conformations to oligomers resulting from dopamine elevation in vivo.   
The toxicity of recombinant oligomers was tested using primary mouse neuronal 
cultures.  Hippocampal neurons were cultured for one week prior to treatment with the 
products of α-synuclein incubation with dopamine or control treatments.  Two weeks 
post-treatment, exogenous α-synuclein from oligomer preparations had become 
internalized within neurons and localized to neurites (Figure 2.6a).  At this timepoint, cell 
viability was evaluated  using  Calcein AM  and  propidium iodide (PI)  dyes.   
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Figure 2.5: Biochemical and structural characterization of α-synuclein oligomers resulting 
from incubation with dopamine in vitro.  (a) Incubation of recombinant wildtype human α-
synuclein under standard aggregation conditions (400 μM, 37°C, 1400 rpm) resulted in 
Thioflavin T (ThioT)-positive fibril formation, whereas ThioT signal was abolished in the 
presence of equimolar dopamine (DA).  rfu, relative fluorescence units.  The data are presented as 
mean ± s.e.m.  (n = 3; repeated measures two-way ANOVA with Bonferroni’s correction for 
multiple comparisons).  (b) α-Synuclein fibrils exhibited characteristic β-sheet secondary 
structure by circular dichroism, while α-synuclein species resulting from interaction with 
dopamine maintained random coil structure on day 5 of incubation.  Representative traces are 
shown.  (c) Sedimentation analysis and coomassie blue staining revealed that over the 6-day 
incubation, in the absence of dopamine, soluble α-synuclein (supernatant) was lost while 
insoluble α-synuclein (pellet) accumulated.  In the presence of dopamine, α-synuclein did not 
become insoluble but instead was detected as multiple soluble oligomer species.  Similar to ex 
vivo oligomers extracted from A53T TH-RREE mice, in vitro generated oligomers were 
immunoreactive to Syn505 (N-terminal) and LB509 (C-terminal) α-synuclein antibodies.  (d) 
Immunoelectron microscopy on α-synuclein from day 4 of incubation with dopamine confirmed 
both Syn505 and LB509 labeling.  Scale bar, 20 nm. **P < 0.01.   
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Figure 2.6: α-Synuclein oligomers 
generated in vitro in the presence of 
dopamine become internalized and are 
toxic to primary neurons.  Hippocampal 
neurons at 7 days in vitro were exposed to 
0.5 or 1 μM α-synuclein oligomer that had 
been prepared in the presence of dopamine 
(Olig), or 1 μM monomer (Mon), 1 μM 
dopamine that was incubated in parallel to 
oligomers but without  α-synuclein (DA), or 
an equivalent dose of PBS.  (a) Two weeks 
post-treatment with 1 μM Olig or PBS, cells 
were labeled with human α-synuclein 
antibodies in a two-stage protocol.  Cells 
were live-incubated with Syn204 antibody 
to label extracellular α-synuclein. Following 
fixation and permeabilization, the cells were 
incubated with LB509 to label total α-
synuclein.  Confocal imaging showed 
puncta that were labeled by LB509 but not 
Syn204, indicating that exogenous 
oligomers had been internalized.  These 
puncta were localized to neurites.  Scale bar, 
10 μm.  (n = 3).  (b-c) At two weeks post-
treatments, cell viability was assayed using 
Calcein AM and propidium iodide (PI) 
dyes.  The number of viable cells, defined as 
Calcein AM positive and PI negative, was 
significantly reduced by exposure to 1 μM 
Olig but was not affected by Mon or DA 
controls.  Treatment with 0.5 μM Olig was 
insufficient to induce toxicity, indicating 
that the effect is dependent on dose.  Scale 
bar, 100 μm.  The data are presented as 
mean ± s.e.m.  (n = 4 except n = 3 for PBS 
and DA, and n = 5 for 1 μM Olig; one-way 
ANOVA with Tukey’s correction for 
multiple comparisons).  *P < 0.05, **P < 
0.01.  
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Exposure of neurons to 1 μM dopamine-incubated α-synuclein induced a significant 44% 
reduction in Calcein positive-PI negative cells relative to PBS treated controls (Figure 
2.6b-c).  Treatment with equivalent doses of monomeric α-synuclein, or dopamine that 
had been incubated under aggregation conditions but without α-synuclein, did not reduce 
cell  viability  (Figure 2.6b-c).   The  observed  neurotoxicity  can  therefore be  attributed 
specifically to α-synuclein oligomers, consistent with our findings in vivo linking 
dopamine-modified species with severe nigrostriatal degeneration. 
 
2.4 Discussion 
In this study we used a novel lentiviral vector approach to enhance dopamine 
levels specifically in the SN of transgenic mice expressing the human A53T familial PD 
mutant of α-synuclein.  In this well-characterized mouse model, the SN does not develop 
α-synuclein inclusions and does not undergo neuronal cell loss (Giasson et al., 2002).  
However, elevation of dopamine induced significant nigrostriatal degeneration and a 
previously undescribed ambulatory phenotype in A53T mice.  Neurodegeneration of the 
SN was not observed in NonTg mice receiving the same treatment, indicating that 
dopamine-induced toxicity is dependent on α-synuclein expression.  Furthermore, we 
demonstrate for the first time in vivo, dopamine-mediated changes in the total levels of  
α-synuclein oligomers as well as their biochemical and functional properties, suggesting 
that disrupting this interaction may be a promising new target in PD treatment. 
Dopamine has long been considered a contributor to the death of dopaminergic 
neurons in disease (Fahn and Cohen, 1992; Jenner and Olanow, 1996; Stokes et al., 
1999).  The acidic conditions within synaptic vesicles serve to maintain 
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dopamine in a reduced state.  However, at physiological pH in the cytosol, dopamine 
readily auto-oxidizes to form reactive quinone species, hydrogen peroxide, and other 
electrophiles (Graham, 1978).  Despite the importance of understanding mechanisms of 
dopamine neurotoxicity, few studies have examined the role of dopamine in SN 
neurodegeneration in vivo.  Intrastriatal injection of dopamine in rats resulted in protein-
bound catechols and injury to dopaminergic nerve terminals after seven days.  The size of 
the lesion was correlated with increasing concentrations of dopamine, and was 
diminished by co-administration with glutathione or ascorbate indicating that oxidation of 
dopamine was responsible for the injury (Hastings et al., 1996).  Transgenic mice 
expressing 5% of normal VMAT2 levels had an age-dependent decline in striatal 
dopamine that was accompanied by decreased rotarod performance without degeneration 
of the SN (Colebrooke et al., 2006).  In the same transgenic mice, a mild progressive 
nigrostriatal degeneration in aged mice was reported (Caudle et al., 2007).  These studies 
indicate that cytosolic dopamine could be toxic, but the long-term effects of raising 
nigrostriatal dopamine levels has remained unknown.   
The present study provides the first investigation of dopamine toxicity by chronic 
enhancement of dopamine synthesis in vivo.  By expressing a mutant TH enzyme lacking 
residues that are critical for feedback inhibition by dopamine (Nakashima et al., 2002; 
Mazzulli et al., 2006; 2007), striatal dopamine in NonTg mice was increased by over 
50%.  Surprisingly, this significant perturbation of dopamine homeostasis was 
insufficient to induce SN degeneration.  NonTg TH-RREE mice maintained a normal 
number of neurons in the SN, intact synaptic contacts with the striatum, and robust motor 
coordination/balance.  The fate of excess dopamine in these animals is likely 
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release into the synapse, leading to the observed increase in locomotion.  This is 
consistent with other studies in which increased extracellular dopamine in the striatum 
resulted in hyperactivity (Zhuang et al., 2001; Lohr et al., 2014).  Dopamine can therefore 
be well-tolerated in the absence of an additional burden or defect. 
α-Synuclein has been independently linked to PD through the discovery of 
dominantly inherited mutations and multiplications of the SNCA gene (Polymeropoulos et 
al., 1997; Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et al., 2004; Zarranz 
et al., 2004; Proukakis et al., 2013; Lesage et al., 2013; Pasanen et al., 2014; Ferese et al. 
2015).  In non-familial PD, which accounts for roughly 90% of cases, aggregated wild 
type α-synuclein is present in Lewy body and Lewy neurite inclusions (Spillantini et al., 
1997; Baba et al., 1998).  Efforts to model PD by transgenic overexpression of               
α-synuclein in mice have yielded mixed results.  Expression of wild type α-synuclein 
under the PDGF-β promoter resulted in atypical non-fibrillar α-synuclein inclusions and 
reduced TH immunoreactivity in the striatum without overt dopaminergic cell loss 
(Masliah et al., 2000).  In mice expressing human wild type or familial mutants (A30P, 
E46K, or A53T) of α-synuclein under the PrP promoter, the SN was consistently spared 
of both neurodegeneration and α-synuclein inclusion pathology, despite the development 
of Lewy body-like inclusions in other regions specifically in A53T transgenic mice 
(Giasson et al., 2002; Lee et al., 2002; Gispert et al., 2003; Gomez-Isla et al., 2003; 
Yavich et al., 2005; Martin et al., 2006; Emmer et al., 2011.)  Similarly, Thy1-driven 
expression of human A30P α-synuclein did not result in histopathological changes or 
neuron loss in the SN, possibly due to low levels of transgene expression (Rathke-
Hartlieb et al., 2001; Neumann et al., 2002).  Targeting wild type, A30P, or A53T 
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human α-synuclein expression specifically to dopaminergic neurons using the TH 
promoter was insufficient to produce either nigrostriatal degeneration or Lewy body-like 
α-synuclein pathology (Rathke-Hartlieb et al., 2001; Matsuoka et al., 2001; Richfield et 
al., 2002).  Greater success inducing dopaminergic cell death was achieved using 
bacterial artificial chromosome transgenic mice expressing human wild type α-synuclein 
(Janezic et al., 2013) or by conditional expression of human wild type or A53T α-
synuclein (Nuber et al., 2008; Lin et al., 2012).  In our study, we used transgenic mice 
with PrP-driven expression of A53T α-synuclein (Giasson et al., 2002).  In late age, these 
mice have a documented increase in basal dopamine levels in the striatum relative to 
NonTg mice (Tsika et al., 2010), which is consistent with our quantification of both 
catecholamines and DAT levels.  However, degeneration of the SN does not occur in 
A53T mice without further enhancement of dopamine levels by TH-RREE expression.   
In stark contrast to NonTg mice, elevation of dopamine levels in A53T mice 
resulted in previously undescribed, progressive nigrostriatal degeneration with a 
locomotor impairment, markedly improving this mouse as a model of PD.  Within 2.5 
months after TH-RREE vector injection into A53T mice, dopaminergic innervation to the 
striatum assessed by VMAT2 had decreased by 25%, while cell bodies in the SN 
remained intact.  By 5 mpi, denervation had progressed to 62% loss of VMAT2-positive 
fibers with corresponding decrease in DAT, and a significant loss of neurons had 
occurred.  These degenerative changes coincided with a reduction of dopamine levels in 
the striatum, and the development of a hypoactive phenotype.  Notably, the initial 
increase in dopamine in A53T TH-RREE mice at 2.5 mpi was not accompanied by 
hyperactivity, as observed in NonTg TH- RREE mice at 5 mpi, consistent with an 
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underlying loss of terminals and dopaminergic dysfunction at this early timepoint.  At 5 
mpi, A53T TH-RREE mice showed significantly reduced ambulation despite dopamine 
concentrations similar to age-matched A53T controls.  This may reflect a functional 
imbalance among synapses that were lost and those that remained and were 
overproducing dopamine (from TH-RREE expression).  There was no change in the 
amount of dopamine receptors or DARPP-32, further supporting a presynaptic basis for 
the locomotor deficit.     
The observed toxicity of dopamine only in A53T mice pointed to a potential 
synergistic role of dopamine and α-synuclein in mediating neurodegeneration.  In cell-
free systems, oxidized dopamine has been shown to kinetically stabilize soluble             
α-synuclein oligomers (Conway et al., 2001; Norris et al., 2005; Cappai et al., 2005; 
Follmer et al., 2007).  In SH-SY5Y cultures expressing A53T α-synuclein, dopamine was 
able to reduce large intracellular aggregates and increase steady-state levels of soluble 
oligomers (Mazzulli et al., 2006; 2007).  α-Synuclein oligomers are thought to be 
neurotoxic species.  Lentiviral vector delivery of artificial α-synuclein variants with 
enhanced oligomerization into the rat SN resulted in the selective loss of dopaminergic 
cells (Winner et al., 2011).  Similarly, artificial mutants with impaired β-sheet structure 
and increased propensity to form oligomers induced degeneration of dopaminergic nerve 
terminals when expressed in worms and overt dopamine cell loss in flies (Karpinar et al., 
2009).  However, the toxicity of dopamine-induced α-synuclein oligomers is largely 
unexplored.  Evidence from studies conducted in vitro suggests that these species can 
block their own degradation and that of other substrates by chaperone-mediated 
autophagy (Martinez-Vicente et al., 2008), and may also reduce neurotransmitter 
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release by inhibition of SNARE complex formation (Choi et al., 2013).  Moreover, the 
toxicity of endogenous cytosolic dopamine in cultured fetal human dopaminergic neurons 
was linked to accumulation of soluble α-synuclein protein complexes (Xu et al., 2002).   
Critically, the effects of dopamine on α-synuclein oligomerization in vivo have 
not been investigated.  We therefore sought to determine if A53T TH-RREE mice had 
alterations in oligomer biochemical and/or functional properties.  Soluble α-synuclein 
oligomers were extracted from the SN and enriched by SEC under non-denaturing 
conditions in order to preserve native conformations.  Increasing dopamine resulted in 
greater total levels of α-synuclein oligomers detected by western blot.  The oligomers 
included species with Stokes radii of up to 65 Å that were also detected in A53T CtrlVect 
mice, consistent with previous characterization of oligomers in aged A53T mice (Tsika et 
al., 2010).  Larger oligomers of up to 122 Å were uniquely observed in A53T TH-RREE 
mice, suggesting that dopamine is capable of modifying oligomer conformations.  These 
species may reflect dopamine-induced remodeling of existing oligomers, and/or 
formation of oligomers from α-synuclein monomers de novo.  Additionally, oligomers 
with larger Stokes radii may contain a greater number of monomer units than lower Å 
species, and/or occupy less compacted arrangements.   
Multiple biochemical and imaging approaches were employed to further 
characterize the oligomers extracted from SN.  In addition to the well-established 
methods such as western blotting and SEC, immunoelectron microscopy was performed 
on SEC fractions to visualize mouse-derived α-synuclein oligomers.  Currently, there is 
no accepted method of specifically imaging α-synuclein oligomers in brain tissue in situ.  
However, with our approach, we were able to identify and image oligomers of known 
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Stokes radii.  Oligomer species from both A53T TH-RREE and A53T CtrlVect mice 
were labeled with antibodies directed at the N- or C-terminus of α-synuclein, suggesting 
that epitopes at both ends of the protein were exposed.  These epitopes were also exposed 
in soluble α-synuclein oligomers generated with dopamine in vitro, consistent with 
previous imaging by immunoelectron microscopy of recombinant dopamine-induced     
α-synuclein oligomers (Norris et al., 2005).  Furthermore, LB509 and Syn505 antibodies 
are known to react robustly with α-synuclein in pathological inclusions in human disease 
brain (Jakes et al., 1999; Duda et al., 2002).  The reactivity of both mouse-derived and 
recombinant oligomers with these antibodies suggests they may share disease-associated 
conformations.   
Unlike the α-synuclein species extracted from A53T CtrlVect mice, oligomers 
from A53T TH-RREE mice were unable to act as seeds for α-synuclein fibrillization in 
vitro.  These data are consistent with the known kinetic arrest of recombinant α-synuclein 
oligomers comprised of primarily random coil structure in the presence of dopamine 
(Conway et al., 2001; Norris et al., 2005).  In a comparison of different oligomer species 
generated in vitro, α-synuclein oligomers that were toxic to SH-SY5Y cultures were also 
incapable of seeding intracellular aggregation of α-synuclein.  Conversely, seeding-
competent oligomers were found to be non-toxic when applied to SH-SY5Y cells 
(Danzer et al., 2007).  These findings are in line with both our in vivo findings and the 
observed toxicity of recombinant dopamine-induced oligomers in primary neuronal 
cultures.  Dopamine-modified species may resist sequestration into non-toxic fibrils or 
inclusions, and may therefore be available to participate in toxic interactions that 
ultimately drive neuron death.   
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Collectively, this work underscores the potential critical importance of the 
interaction of dopamine and α-synuclein in driving disease.  In PD, dopaminergic 
terminals are thought to degenerate prior to cell bodies (Cheng et al., 2010), suggesting 
that the disease may arise at the synapse.  Increasing dopamine levels in A53T mice 
recapitulated the substantial loss of terminals that precedes overt nigral cell death, 
offering a new model of disease progression in PD.  These mice also underwent an 
eventual decline in dopamine levels and developed an associated motor deficit, 
mimicking the depletion of striatal dopamine and resulting hypokinesia that occurs in PD.  
Our findings also demonstrate that dopamine modifies α-synuclein aggregation in vivo, 
resulting in oligomer conformations that are biochemically and structurally similar to 
neurotoxic oligomers induced by dopamine in vitro.  Dopamine-modified α-synuclein 
species may mediate neurodegeneration through the disruption of cellular membranes as 
previously proposed (Sulzer et al., 2001).  Moreover, damage to synaptic vesicle 
membranes could lead to dopamine leakage and further induction of pathogenic α-
synuclein oligomers. 
 
2.5 Materials and Methods 
Animals.  The mice used in this study were homozygous for expression of human 
A53T α-synuclein under the mouse PrP promoter (line M83).  These mice undergo spinal 
cord degeneration at approximately 18 months of age in our colony, and the phenotype 
has been described previously (Giasson et al., 2002).  Any animals showing symptoms of 
spinal cord degeneration, i.e.  hunched back, altered gait, or hindlimb paralysis, were 
excluded from the study.  NonTg littermates were also used for experiments.  No care 
 56
was taken as to the sex of the animals.  Mice were randomly assigned to the lentiviral 
vector injection groups. 
Production of Lentiviral Vectors and Determination of Titer.  Generation of 
human tyrosine hydroxylase-1 containing the R37E/R38E mutation (TH-RREE) 
construct has been previously described (Mazzulli et al., 2006).  The coding sequence 
was removed from the pcDNA3.1 vector and was subcloned into the self-inactivating 
pTY-linker lentiviral expression vector at the Pme1 site downstream of the CMV 
promoter.  Generation of replication-deficient pseudotyped HIV-derived lentiviral vectors 
was achieved by transient co-transfection of HEK293T cells with the expression vector 
along with the vectors carrying the additional transcripts required for encapsulation, 
packaging and envelope proteins.  24 hours after the cells were seeded into 150 mm 
dishes coated with poly-D-Lysine they were transiently transfected with a mixture 
containing 550 µg of the pTY-TH-RREE expression vector, 357.5 µg of CMVD82 
packaging vector, and 192.5 µg of pVSV-G envelope vectors using the calcium 
phosphate transfection protocol.  The culture medium was changed every day and the 
media containing the virus was collected 72 hours post-transfection, filtered through 0.45 
µm membranes, and concentrated by ultracentrifugation at 50,000 g for 2 hours at 4°C.  
The viral pellet was subsequently re-suspended in 800 µL of DMEM medium to make a 
concentrated viral stock.  An empty vector control virus containing all elements except 
for the TH-RREE gene (CtrlVect) was generated in parallel and both viruses were 
obtained from the University of Pennsylvania Vector Core.   
To determine vector functionality and viral titer, SH-SY5Y human neuroblastoma 
cells (American Type Culture Collection) were plated in 24-well plates at 5x104 
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cells/well in DMEM/F12 medium containing 10% heat-inactivated fetal bovine serum, 
100 U/ml penicillin, and 100 µg/ml streptomycin.  The cells were allowed to recover for 
2 days and were then differentiated for 5 days with 20 µM retinoic acid.  The cells were 
infected with different dilutions of lentivirus containing either an empty vector or        
TH-RREE expression vector and the viral titers were calculated by TH 
immunocytochemistry.   
Stereotaxic Injection of Lentiviral Vector into the SN.  A53T α-synuclein 
transgenic mice or non-transgenic littermates received bilateral lentiviral vector injections 
at 10 months of age.  The mice were placed into an anesthesia chamber connected to an 
isofluorane delivery system to induce anesthesia.  The mice were then placed into a 
stereotaxic head holder, an anesthesia mask was fitted, and an incision was made in the 
skin.  Small bilateral holes were drilled into the skull according to the coordinates for the 
SN in the mouse brain (anterior-posterior -3.3 mm from bregma, mediolateral 1 mm) and 
a 30g Hamilton syringe was inserted slowly to 4 mm dorsoventral depth.  2 µl of the viral 
concentrate (5x107 IU/ml) was injected into the SN at a rate of 0.25 µl/min, and the 
needle was left in place for an additional 5 min before being slowly withdrawn, in order 
to minimize leakage of the injected fluid.  The skin was sutured sterilely and the animals 
were monitored until they recovered from anesthesia.  All animal work was conducted 
according to National Institute of Health guide for the care and use of laboratory animals 
and were approved by the Children’s Hospital of Philadelphia. 
Motor Function Testing.  All behavioral tests were conducted 1 week prior to 
sacrifice.  Mice were habituated to the testing room for 2 hours before testing.  To 
measure open field activity, the mice were singly housed and the cage was placed 
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inside a laser monitoring device consisting of an open, rectangular frame containing 
sensors (Opto-M3 activity meter, Columbus Instruments).  The number of infrared beam 
breaks was quantified over a 12-hour period during the dark cycle from 6 pm to 6 am 
using Multi Device Interface software (Columbus Instruments).  Data was collected for 3 
consecutive days for each animal, and the average of the 3 days was used as n = 1 for 
each mouse.  Food and water were available ad libitum. 
To assess motor coordination and balance, mice were tested on the Rotarod (Ugo 
Basile, model 7650).  The mice were acclimated to the apparatus with four training 
sessions of 5 min each at 4 rpm, followed by 5 min of rest in the home cage.  Testing was 
performed one hour later with two trials in which speed was accelerated from 4 to 40 rpm 
in 300 sec.  The latency to fall off the rotarod within this time period was recorded and 
the average of the two trials was used as n = 1 for each mouse.   
Immunohistochemistry and Stereological Cell Counts.  For histological 
analysis the mice were deeply anesthetized and perfused transcardially with saline 
followed by 4% PFA in 0.1 M phosphate buffer (pH 7.4).  The brains were post-fixed 
overnight at 4°C in 4% PFA and then cryoprotected in 30% sucrose solution for 2 days at 
4°C.  The brains were submerged in dry ice-chilled isopentane for 30 sec and then stored 
at -80°C until sectioning.  On the day of sectioning, brains were mounted on chucks with 
OCT (Tissue-Tek) and the brainstem, SN, and striatum were each sectioned using a 
cryostat (Leica, Jung Frigocut 2800N).  Free-floating coronal sections of alternating 10 
and 30 μm thickness were collected from each region and stored at 4°C in 0.1 M 
phosphate buffer containing 0.01% sodium azide. 
The sections were quenched in 5% H2O2 in methanol for 30 min, followed by 
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antigen retrieval by boiling in citrate solution pH 6 for 10 min.  The tissue was blocked 
for 1 hour at RT with 5% NGS, 3% BSA in PBS containing 0.1% Triton X-100, and then 
incubated overnight at 4°C  with primary antibody diluted in blocking buffer.  Antibodies 
were used against VMAT2 (rabbit, 1:20000; courtesy of Dr. Gary Miller at Emory 
University, Atlanta, GA), TH (rabbit, 1:2000, Calbiochem 657012), and Syn505 (mouse, 
1:5000, courtesy of Dr. Virginia M. Lee at University of Pennsylvania, Philadelphia, PA).  
Incubation with biotin-conjugated secondary antibodies was followed by avidin-biotin-
peroxidase complex, each for 1 hour at RT, and visualization by 3,3-diaminobenzidine 
(DAB) for 1 min (ABC Elite, Vector Laboratories).  In some cases, sections were 
counterstained with Cresyl Violet.  The tissue was then mounted, dehydrated in an 
increasing alcohol series and cleared in xylenes, and coverslipped with Permount 
mounting medium.  Slides were scanned by the Children’s Hospital of Philadelphia 
Pathology Core facility.  Quantification of VMAT2 staining intensity in the striatum was 
performed using Image J software (National Institutes of Health). 
Unbiased stereological quantification of neurons in the SN was performed as 
described previously (Tieu et al., 2003).  Briefly, 30 μm sections spaced 90 μm apart 
were selected in order to represent the full rostro-caudal axis of the SN.  The sections 
were stained with Cresyl Violet and the Nissl-positive neurons were blindly counted 
using the optical fractionator method (StereoInvestigator; MBF Bioscience).   
Catechol Quantification by HPLC with Electrochemical Detection.  Striatal 
tissues were homogenized by sonication in 10 volumes of 0.1 M perchloric acid 
containing 1 µM 3,4 dihydroxybenzylamine as an internal standard.  The samples were 
centrifuged at 16,000 g for 10 min at 4°C and the supernatants were filtered through 
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0.22 µm filters.  Catechols were resolved on a reverse-phase C18 Luna column (150x4.6 
mm, 5 µm; Phenomenex) as previously described (Mazzulli et al., 2006).  Protein pellets 
were solubilized in 50 mM Tris pH 7.4 containing 2% SDS and protein concentration 
was determined using the BCA microassay kit (Pierce).  Monoamine levels were 
normalized to protein concentration and expressed as femtomoles analyte /µg of protein.   
Sequential Extraction and Native Size Exclusion Chromatography.  Striatal or 
SN tissue from individual mice was homogenized in 10 volumes of lysis buffer: 1% 
Triton X-100 in 20 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EGTA, and 
protease inhibitor cocktail (P2714, Sigma).  The tissue was grinded with a mechanical 
homogenizer and centrifuged at 16,000 g for 10 min at 4°C.  The pellet was further 
extracted by sonication in 2% SDS, 50 mM Tris pH 7.4 with protease inhibitor cocktail, 
boiling at 95°C for 10 min, and centrifugation at 16,000 g for 10 min.  The resulting 
supernatant was designated the Triton-insoluble fraction.  Protein concentration was 
determined using the BCA assay (Pierce). 
For size exclusion chromatography (SEC), 500 µg of Triton-soluble SN tissue in a 
total volume of 270 µl was loaded onto a Superdex 200 HR10/30 column (GE 
Healthcare) connected to an Agilent 1100 series HPLC system.  Mobile phase consisted 
of 25 mM HEPES and 150 mM NaCl, pH 7.25 and the flow rate was set to 0.3 mL/min.  
Fractions corresponding to 122-94, 94-81, 81-72, 72-65, 65-59, 59-54, 54-50, 50-45, 45-
41, 41-38, 38-34, and 34-32 Å were each pooled and concentrated with 3,000 NMWL 
Ultracel Microcon filters (Millipore).  Fractions 122-72, 65-41, and 38-32 were further 
combined to enhance the α-synuclein signal on SDS-PAGE.  The SEC column was 
calibrated using globular protein standards (GE Healthcare). 
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Western Blotting.  Proteins sequentially extracted or further fractionated by SEC 
were run on 10 or 12% SDS-PAGE gels and transferred to PVDF membranes.  The 
membranes were blocked for 1 hour at RT in 5% (w/v) milk in 20 mM Tris pH 7.4, 150 
mM NaCl and 0.1% Tween.  Incubation with primary antibodies diluted in blocking 
buffer was overnight at 4°C.  Antibodies used against synaptic proteins were TH (rabbit, 
1:4000, Calbiochem 657012), DAT (rat, 1:1000, Millipore MAB369), D1 receptor (rat, 
1:1000, Sigma D2944), D2 receptor (rabbit, 1:1000, Millipore AB5084P), DARPP-32 
(rabbit, 1:1000, Cell Signaling 2306S).  Antibodies directed against α-synuclein were 
LB509 (mouse, 1:1000), Syn505 (mouse, 1:1000), and SNL-4 (rabbit, 1:1000), all 
courtesy of Dr. Virginia M. Lee at University of Pennsylvania, Philadelphia, PA.  
Loading controls for Triton-soluble proteins were GAPDH (mouse, 1:10000, Abcam 
ab8245), NSE (rabbit, 1:4000, Abcam ab53025), and Actin (rabbit, 1:1000, Sigma 
A2066).  The loading control for Triton-insoluble proteins was Vimentin (mouse, 1:1000, 
Abcam ab8069).  Membranes were incubated for 1 hour at RT with secondary antibodies 
conjugated to IRDye 680 or 800 (1:5000, Rockland) and then scanned using an Odyssey 
Infrared Imaging System (Li-Cor).  Quantification of protein levels was performed using 
ImageStudio software (Li-Cor) and was normalized to loading control levels.  For α-
synuclein oligomer bands, all individual immunobands >19 kD that were detected were 
quantified and the intensities summed, and the total was divided by the total NSE.   
Near-infrared (nIRF) scanning of oxidized catechols was performed as described 
previously (Mazzulli et al., 2016).  Briefly, prior to transfer the SDS-PAGE gels were 
scanned in the 700 nm channel at intensity 10 on an Odyssey Infrared Imaging System 
(Li-Cor).   
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Immunoelectron Microscopy of SEC Fractions.  SEC fractions from SN tissue 
corresponding to low (41-65) and high (72-122) Å Stokes radii or dopamine-incubated 
recombinant α-synuclein were applied to 300 mesh carbon-coated grids and blocked with 
1% BSA in 20 mM Tris pH 7.4, 150 mM NaCl.  The α-synuclein oligomers were labeled 
with the Syn505 antibody against the N-terminus or LB509 antibody against the C-
terminus, followed by 10 nm gold conjugated secondary (Electron Microscopy Sciences).  
Grids were negatively stained with 1% uranyl acetate and imaged at the University of 
Pennsylvania Electron Microscopy Resource Laboratory.  Control samples were 
immunodepleted of α-synuclein (see below) prior to grid preparation or had primary 
antibody omitted. 
In Vitro Aggregation and Seeding Assays.  Recombinant human wild type α-
synuclein was expressed and purified as described previously (Tsika at el., 2010).  
Purified α-synuclein was incubated at 6 mg/mL (415 µM) with or without equimolar 
dopamine at 37°C and shaking at 1400 rpm for up to 6 days.  At indicated time points, 
fibrillar content of the reaction mixture was assayed by the addition of Thioflavin T 
(Sigma) to a final concentration of 25 µM.  Fluorescence emission was measured at 482 
nm during excitation at 450 nm.  Sedimentation analysis was performed by centrifugation 
at 16,000 g for 10 min at 4°C.  The supernatants and pellets were boiled in SDS sample 
buffer at 95°C for 10 min.  α-Synuclein aggregates were resolved by SDS-PAGE and the 
gels were stained with Coomassie Blue R-250.  Circular dichroism spectra were obtained 
using a Jasco J-810 spectropolarimeter at the Children’s Hospital of Philadelphia Protein 
Core facility.  The protein was diluted to 20 µM in 0.05 M KH2PO4 pH 7.8.  Spectra were 
corrected for baseline measurement of an equivalent volume of PBS diluted in 
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KH2PO4 buffer. 
Seeding assays were performed by incubating 5 µg total protein from pooled 
oligomeric SEC fractions (41-122 Å) with 425 µg fresh recombinant α-synuclein (300 
µM final concentration) at 37°C and shaking at 1400 rpm.  Aliquots at indicated time 
points were analyzed by Thioflavin T.  To immunodeplete α-synuclein for control 
samples, pooled SEC fractions were incubated overnight at 4°C with LB509 antibody at a 
1:5 ratio of antibody to total µg protein.  Protein G-conjugated beads (Sigma) were 
equilibrated in 25 mM HEPES, 150 mM NaCl, pH 7.4 and incubated with the 
immunocomplexes for 1 hour at 4°C.  α-Synuclein oligomers were then pulled down by 
centrifugation at 2000 g for 2 min, and the resulting supernatant was used for 
experiments.  
Primary Neuronal Cultures.  Hippocampal neurons were provided by the 
University of Pennsylvania Neuron Culture Service Center.  After dissection from 
C57BL/6 mouse embryos at day 18-19, cells were mechanically dissociated, trypsinized, 
and seeded at 100,000 cells per well into 24-well plates freshly coated with 50 µg/ml 
poly-D-lysine (Sigma).  After plating, neurons were cultured for 2 hours in culture media 
containing 5% heat-inactivated fetal bovine serum, 1% Glutamax, 2% B-27 supplement, 
100 U/ml penicillin, 100 µg/ml streptomycin in Neurobasal media (all from Invitrogen).  
After 2 hours, the media was changed to culture media without fetal bovine serum to 
discourage survival of glial cells. Twice per week, half of the media was replaced with 
fresh culture media. 
Following one week in culture, neurons were treated with dopamine-incubated    
α-synuclein (from day 4-6 of in vitro aggregation) at a final concentration of 1 
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µM.  Control conditions were equivalent doses of PBS, monomeric α-synuclein, or 
dopamine that had been incubated in parallel under aggregation conditions but without α-
synuclein.  Two weeks post-treatment, cell viability was assayed using calcein AM 
(Sigma) and propidium iodide (PI) (Sigma) incubated for 20 min at RT at final 
concentrations of 3 µM in PBS.  Fluorescence images were obtained using MetaMorph 
software (Molecular Devices) and an inverted Olympus IX70 microscope equipped with 
an IX-FLA fluorescence observation attachment (Olympus Optical Co., Tokyo, Japan).  
For quantification of viable cells (calcein-positive and PI-negative), 10 random fields of 
view were blindly counted per well, with at least 100 total cells counted per replicate.  
To image human α-synuclein in treated neurons, cells were labeled in a two-stage 
protocol as previously described (Volpicelli-Daley et al., 2011).  Two weeks following 
treatment, cells were live-incubated in media containing Syn204 antibody (mouse IgG2a, 
1:500) for 1 hour at 4°C to label extracellular α-synuclein.  The cells were then fixed with 
4% PFA for 20 min at RT, and permeabilized with 0.1% Triton X-100 in 5% NGS, 3% 
BSA in PBS for 1 hour at RT.  Cells were incubated with LB509 (mouse IgG1, 1:500) 
overnight at 4°C to label both extracellular and intracellular α-synuclein.  Secondary 
antibodies conjugated to Alexa Fluor (anti-mouse IgG1 488, 1:500, Thermo Fisher 
A21121; anti-mouse IgG2a 594, 1:500, Thermo Fisher A-21135) were incubated for 1 
hour at RT.  The staining was imaged by laser-scanning confocal microscopy (Olympus 
Fluoview). 
Statistics.  All statistical analysis was done using Prism 6 software (GraphPad). 
Two-tailed unpaired Student’s t test was used for all comparisons between two groups.  
For comparisons with multiple groups, one- way ANOVA with Tukey’s correction for 
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multiple comparisons was used.  Specifically for Thioflavin T assays with multiple 
groups measured over time, repeated-measures two-way ANOVA with Tukey’s or 
Bonferroni’s correction for multiple comparisons was used.  All experiments were 
performed at least twice, with measurements from the same samples treated as technical 
replicates and averaged to obtain final values. 
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2.7 Supplementary Information 
 
Figure 2.S1: Increased TH expression and steady-state catecholamine concentrations in  
SH-SY5Y cells transduced with TH-RREE vector.  (a) Schematic representation of the 
lentiviral vectors used in this study.  TH-RREE contained the gene for human tyrosine 
hydroxylase isoform 1 (hTH-1) with mutations R37E, R38E rendering TH insensitive to feedback 
inhibition by dopamine.  The gene was absent from the empty vector control (CtrlVect), while all 
other elements were retained.  (b) Western blot analysis of lysates showed TH protein only in 
TH-RREE transduced cells.  Neural specific enolase (NSE) was used as a loading control.  (c) TH 
immunofluorescence confirmed expression in TH-RREE transduced cells.  Scale bar, 100 μm.  
(d) Catecholamines were detected in cells treated with TH-RREE lentivirus.  ND, not detected.  
The data are presented as mean ± s.e.m.  (n = 3 except n = 6 for DA TH-RREE and DOPAC TH-
RREE).   
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Figure 2.S2: TH-RREE vector increases TH expression in A53T mice.  (a) TH levels were 
increased in the striatum in A53T TH-RREE mice compared with A53T CtrlVect at 5 mpi.  
GAPDH was used as a loading control.  The data are presented as mean ± s.e.m.  (n = 3; two-
tailed unpaired Student’s t test).  (b) TH staining was increased in both the SN (left panels) and 
striatum (right panels) of A53T TH-RREE mice at 5 mpi.  Cresyl Violet (Nissl) counterstain.  
Scale bar, 10 μm.  *P < 0.05. 
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Figure 2.S3: Postsynaptic markers remain unchanged by lentiviral vector treatment.   
Striatal levels of D1 (a,b) and D2 (a,c) postsynaptic receptors were unaltered in TH-RREE 
injected A53T and NonTg mice compared with CtrlVect-injected mice.  The postsynaptic 
signaling molecule DARPP-32 was also unaffected by viral treatment (a,d).  All quantification 
was normalized to actin loading control.  The data are presented as mean ± s.e.m.  (D1R, n = 3 
except n = 4 for NonTg CtrlVect; D2R, n = 3 except n = 4 for NonTg CtrlVect; DARPP-32, n = 
3; one-way ANOVA with Tukey’s correction for multiple comparisons). 
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Figure 2.S4: Loss of striatal dopamine in A53T mice cannot be accounted for by metabolism 
to DOPAC or formation of dopamine-protein adducts.  (a) Levels of DOPAC in the striatum 
remained unchanged over time regardless of lentiviral treatment.  The data are presented as mean 
± s.e.m.  (CtrlVect, n = 3; TH-RREE, n = 6 for 2.5 mpi and n = 4 for 5 mpi; one-way ANOVA 
with Tukey’s correction for multiple comparisons).  (b-c) Triton-soluble (S) and insoluble (P) 
extracts of striatal tissue from mice at 2.5 or 5 mpi were analyzed by SDS-PAGE and near-
infrared fluorescence (nIRF).  Total levels of dopamine-protein adduct (combined soluble and 
insoluble nIRF signal) did not change either between injection groups or within groups over time.  
The data are presented as mean ± s.e.m.  (n = 3; one-way ANOVA with Tukey’s correction for 
multiple comparisons). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.S5: Analysis of inclusion pathology and insoluble α-synuclein in A53T mice.  (a) 
Regardless of lentiviral treatment, α-synuclein inclusion pathology, as detected by Syn505 
staining, was abundant in brainstem (BS) and absent in SN of A53T mice at 5 mpi.  Scale bar, 20 
μm.  (b-d) At 5 mpi, SN from A53T mice was sequentially extracted with buffers containing 1% 
Triton followed by 2% SDS.  Triton-insoluble/SDS-soluble fractions from A53T TH-RREE and 
A53T CtrlVect contained similar levels of monomeric α-synuclein as assessed by LB509 (b), 
Syn211 (c), and SNL-4 (d) antibodies.  Vimentin (Vim) was used as a loading control, and 
appears for Syn211 and SNL-4 as the same blot since the same membrane is shown.  The data are 
presented as mean ± s.e.m.  (LB509, n = 3; Syn211 and SNL-4 n = 6 except n = 4 for CtrlVect; 
two-tailed unpaired Student’s t test).   
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Figure 2.S6: Further characterization of α-synuclein and dopamine derived from A53T 
mice.  (a-b) Triton-soluble SN from A53T TH-RREE and A53T CtrlVect mice at 5 mpi was 
fractionated by size exclusion chromatography, and the resulting fractions were analyzed by 
western blot using α-synuclein antibodies Syn211 (C-terminal) (a) and SNL-4 (N-terminal) (b).  
Oligomer bands that uniquely appear in 122 Å fractions from TH-RREE mice are indicated by 
arrows.  Neural specific enolase (NSE) was used as a loading control, and appears for Syn211 and 
SNL-4 as the same blot since the same membrane is shown.  (n = 4).  (c) The SDS-PAGE gels 
were scanned for near-infrared fluorescence, which revealed oxidized dopamine (arrow) only in 
72-122 Å fractions from A53T TH-RREE mice.  (n = 4).   
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3.1 Abstract 
 α-Synuclein is a conserved, abundantly expressed protein that is partially 
localized in pre-synaptic terminals in the central nervous system.  The precise biological 
function(s) and structure of α-synuclein are under investigation.  Recently, the native 
conformation and the presence of naturally occurring multimeric assemblies have come 
under debate.  These are important deliberations because α-synuclein assembles into 
highly organized amyloid-like fibrils and non-amyloid amorphous aggregates that 
constitute the neuronal inclusions in Parkinson’s disease and related disorders.  Therefore 
understanding the nature of the native and pathological conformations is pivotal from the 
standpoint of therapeutic interventions that could maintain α-synuclein in its 
physiological state.  In this review, we will discuss the existing evidence that define the 
physiological states of α-synuclein and highlight how the inherent structural flexibility of 
this protein may be important in health and disease.  
 
3.2 Introduction 
α-Synuclein is a soluble protein that is highly conserved in vertebrates and 
abundantly expressed in nervous tissue (Jakes et al., 1994).  It was first discovered in 
1988 in association with purified synaptic vesicles from the Torpedo electric ray 
(Maroteaux et al., 1988).  Soon afterward α-synuclein was found to be widely distributed 
across the mammalian brain and localized to presynaptic nerve terminals, suggesting 
functions related to neurotransmission (Iwai et al., 1995).  Independent of these reports, 
α-synuclein was identified as the precursor to a hydrophobic peptide found in 
the non-Aβ component of Alzheimer’s Alzheimer’s disease senile plaques, termed 
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disease amyloid (NAC) (Uéda et al., 1993).  The α-synuclein gene was also dynamically 
regulated during song learning in zebra finch, supporting a role in synaptic plasticity 
(George et al., 1995).   
The discovery of a mutation in the α-synuclein gene that was associated with 
autosomal dominant inheritance of Parkinson’s disease (PD) provided the impetus for a 
major shift in α-synuclein research (Polymeropoulos et al., 1997).  PD is a neuro-
degenerative disorder primarily characterized by the loss of dopamine-producing neurons 
in the substantia nigra pars compacta resulting in motor impairment.  Since the original 
publication of the A53T mutation, several mutations, as well as multiplications of the α-
synuclein gene have been linked to PD (Chartier-Harlin et al., 2004; Krüger et al., 1998; 
Lesage et al., 2013; Pasanen et al., 2014; Proukakis et al., 2013; Singleton et al., 2003; 
Zarranz et al., 2004; Ferese et al. 2015)  Furthermore, several antibodies against α-
synuclein robustly detect the well-known pathoanatomical features of PD, Lewy bodies 
and Lewy neurites, in postmortem brain tissue from patients with sporadic PD as well as 
other related neurodegenerative disorders (Baba et al., 1998; Spillantini et al., 1997; 
Takeda et al., 1998).  The finding that wildtype α-synuclein was detected in Lewy bodies 
and Lewy neurites prompted the publication of numerous studies that investigated the 
biochemistry and biology of α-synuclein.  Despite the rather impressive body of work 
several fundamental questions remain: What is the physiological function of α-synuclein?  
What is the structure of native α-synuclein?  What factors contribute to the induction of 
aggregation-competent conformational states of α-synuclein?  In this review, we will 
briefly review the evidence for the different biological functions and discuss ongoing 
efforts to precisely define physiological structures of α-synuclein.  
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3.3 The physiological function(s) of α-synuclein 
 The initial studies indicated that α-synuclein is not required for neuronal 
development or synapse formation, but instead may modulate synaptic activity.  In 
rodents, α-synuclein is detected close to the time of birth and continues to increase until 
one month of age, when it reaches a steady-state level that is maintained throughout 
adulthood (Shibayama-Imazu et al., 1993).  Similarly, in cultured rat neurons the 
development of synapses precedes α-synuclein expression and translocation to axonal 
terminals (Murphy et al., 2000; Withers et al., 1997).  The hypothesis that α-synuclein 
regulates synaptic activity was directly tested in mice lacking α-synuclein.  α-Synuclein 
null mice develop normal brain architecture and synaptic contacts, and do not exhibit 
gross behavioral phenotypes (Abeliovich et al., 2000).  However, subtle abnormalities in 
activity-dependent neurotransmitter release have been observed.  Upon repeated 
stimulation, dopaminergic synapses from α-synuclein null mice sustain highly elevated 
dopamine release (Abeliovich et al., 2000; Yavich et al., 2004).  Functional redundancy 
among α-synuclein and the other synuclein family members, β- and γ-synuclein, may 
account for the mild phenotypes observed in the single knockout.  In α/β-synuclein 
double knockout mice, synaptic plasticity appears unaltered relative to α-synuclein single 
knockouts, although dopamine levels in the striatum are reduced (Chandra et al., 2004).  
The importance of synucleins is particularly highlighted by α/β/γ-synuclein triple 
knockouts, which have decreased life span and late-onset synaptic dysfunction compared 
with wildtype mice (Burré et al., 2010; Greten-Harrison et al., 2010).  Triple knockouts in 
another study had motor deficits and decreased striatal dopamine, along with abnormal 
dopamine neurotransmission (Anwar et al., 2011).  Collectively, these reports 
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emphasize the important role of the synucleins in long-term synaptic maintenance and 
plasticity.  
 
3.3.1 Synaptic vesicle trafficking   
Examination of the role of α-synuclein in the synaptic vesicle cycle has yielded 
conflicting results.  Depletion of α-synuclein from rodent hippocampal neurons both in 
vivo and in vitro induces a significant loss of undocked synaptic vesicles, suggesting that 
α-synuclein acts to replenish or maintain the resting and/or reserve vesicle pools (Cabin 
et al., 2002; Murphy et al., 2000).  In contrast, another study found that increasing α-
synuclein in rodent hippocampal neurons reduces the recycling pool of vesicles (Nemani 
et al., 2010).  The effect of α-synuclein on vesicles docked at the plasma membrane prior 
to exocytosis is similarly unclear.  Knockout or knockdown of α-synuclein in rodent 
hippocampal neurons results in either a decrease or no change in the number of docked 
vesicles (Cabin et al., 2002; Murphy et al., 2000).  Conversely α-synuclein expression in 
PC12 cells causes an accumulation of vesicles at the plasma membrane and impairment 
of exocytosis (Larsen et al., 2006).  However, in mice modestly overexpressing α-
synuclein (levels are not associated with neurotoxicity), hippocampal synapses display a 
redistribution of vesicles away from the active zone.  The density of vesicles in synaptic 
boutons is also reduced, consistent with α-synuclein-mediated inhibition of vesicle 
clustering.  This is supported by α-synuclein-induced defects in vesicle re-clustering 
following endocytosis in rat hippocampal neurons (Nemani et al., 2010).  Still, opposing 
results have been obtained from yeast, in which α-synuclein expression results in massive 
accumulations of vesicles that co-localize with Rab GTPases (Gitler et al., 2008; 
 77
Chen et al., 2008b).  Likewise, α-synuclein has been shown to restrict vesicle diffusion 
away from synapses in mouse hippocampal neurons (Wang et al., 2014).  Several lines of 
evidence, therefore, support the participation of α-synuclein in synaptic vesicle 
trafficking, though the specific steps for which it may be most important, i.e. vesicle 
docking, recycling and/or re-clustering, remain unclear.  
 
3.3.2 Chaperone-like activity and neurotransmitter release   
α-Synuclein and the other synuclein family members may act as molecular 
chaperones, facilitating neurotransmitter release.  Cysteine-string protein α (CSPα) is a 
chaperone that is essential for synaptic health; its deletion in mice leads to a decrease in 
SNARE protein complexes, nerve terminal degeneration, motor impairment and death.  
When expressed in CSPα-deficient mice, α-synuclein is able to rescue this degenerative 
phenotype and restore levels of SNARE complexes in synaptic terminals.  Moreover, 
mice lacking both α-synuclein and CSPα exhibit an exacerbated phenotypic decline 
(Chandra et al., 2005).  These findings suggest that α-synuclein is able to complement the 
activity of CSPα in promoting synapse integrity.  Direct evidence for the interaction of  
α-synuclein with SNARE complexes was documented by co-immunoprecipitation of α-
synuclein with SNARE proteins and specific binding to the vesicle-associated SNARE 
protein synaptobrevin-2.  In mammalian cells and purified in vitro systems, α-synuclein 
dose-dependently facilitates SNARE complex assembly (Burré et al., 2010).  Additional 
support for chaperone-like activity includes sequence homology between α-synuclein and 
14-3-3 protein chaperones as well as the association of α-synuclein with 14-3-3 and its 
binding partners in rat brain (Ostrerova et al., 1999).  α-, β-, and γ-synucleins are 
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also able to prevent the aggregation of denatured proteins in vitro (Souza et al., 2000a), 
further supporting a conserved chaperone-like function of synucleins and the existence of 
several protein-protein interactions that facilitate synaptic function. 
 
3.3.3 Putative role in neurotransmitter synthesis and reuptake   
Published evidence indicates that α-synuclein-mediated protein-protein 
interactions may modulate dopamine synthesis and recycling.  α-Synuclein may inhibit 
the activity of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine 
synthesis.  α-Synuclein and TH co-immunoprecipitate from rat striatal tissue and MN9D 
dopaminergic cells and α-synuclein was shown to inhibit TH activity in MN9D and PC12 
cells, potentially through PP2A phosphatase-mediated reduction of serine 40 
phosphorylation of TH (Peng et al., 2005; Perez et al., 2002).  α-Synuclein may also 
interact with and inhibit the activity of aromatic amino acid decarboxylase, which 
catalyzes the conversion of L-DOPA to dopamine (Tehranian et al., 2006).  Thus,          
α-synuclein may serve as a negative regulator of dopamine synthesis, though further 
validation of these findings is necessary.  Several reports have also implicated α-
synuclein in the regulation of the dopamine transporter (DAT), though the evidence is 
conflicting with regards to the functional consequences.  Direct binding of α-synuclein to 
DAT has been demonstrated in multiple studies.  However, α-synuclein does not appear 
to alter DAT function, but rather in various cellular contexts can promote or inhibit DAT 
trafficking to the plasma membrane (Oaks and Sidhu, 2011).  Elucidating the relationship 
between α-synuclein and DAT requires further investigation. 
 
 79
3.4 α-Synuclein structural flexibility 
3.4.1 Primary sequence   
The primary sequence of α-synuclein consists of 140 amino acids with a predicted 
molecular mass of 14,460.16 Da and an isoelectric point of 4.67 (Figure 3.1).  The 
sequence of α-synuclein is composed of three functionally defined domains.  The          
N-terminal region (amino acids 1-60) is characterized by the presence of unique and 
highly conserved sequence of imperfect tandem repeats with a central consensus motif of 
K(A)-T(A,V)-K(V)-E(Q,T)-G(Q)-V(A).  These motifs spanning residues 10-86 are 
projected to form two amphipathic α-helices and are characteristic of several proteins 
such as apolipoproteins that bind reversibly to membranes (George et al., 1995; 
Maroteaux et al., 1988).  Indeed the structure of membrane bound α-synuclein contains 
two α-helices (amino acids 3-37 and 45-92) in a roughly antiparallel arrangement with a 
short linking region (Ulmer et al., 2005).  These helices are stabilized by interaction with 
a variety of phospholipid bilayers, though α-synuclein interacts preferentially with 
membranes of high curvature and an abundance of acidic phospholipids, properties 
consistent  with  those  of  synaptic  vesicles  (Davidson et al.,  1998;  Zhu  et al.,  2003a). 
 
 
 
Figure 3.1:  Primary sequence of human α-synuclein.  Green color indicates the imperfect 
tandem repeats.  Known mutations are indicated in red.  The hydrophobic NAC domain is 
underlined.  The major sites of posttranslational modifications identified in vivo are highlighted 
in blue (Ac, acetylation; Ub, ubiquitination; NO2, nitration; and PO3- phosphorylation). 
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 Upon interaction with membranes of low curvature α-synuclein adopts a distinct 
secondary structure characterized by a single extended helix that includes both previously 
described helical domains and the linker region (amino acids 38-44) (Ferreon et al., 2009; 
Georgieva et al., 2010; Trexler and Rhoades, 2009).  All known mutations associated 
with familial PD (A30P, E46K, H50Q, G51D, A53E, and A53T) are found in the N-
terminal domain (Krüger et al., 2008; Lesage et al., 2013; Pasanen et al., 2014; 
Polymeropoulos et al., 1997; Proukakis et al., 2013; Zarranz et al., 2004).  These 
mutations, with the exception of G51D, A53E, and A30P, increase the propensity of α-
synuclein to form insoluble aggregates and produce morphologically distinct aggregate 
species (Ghosh et al., 2014; Giasson et al., 1999; Greenbaum et al., 2005; Lesage et al., 
2013; Mahul-Mellier et al., 2015; Narhi et al., 1999).  Though the precise mechanism by 
which these mutations promote aggregation has not been conclusively shown, evidence 
implicate an accelerated formation of oligomers (Conway et al., 2000b) likely due to the 
destabilization of the native N-terminal conformation (Bertoncini et al., 2005a; Burré et 
al., 2015; Coskuner and Wise-Scira, 2013; Dettmer et al., 2015). 
Amino acids 61-95 compose the hydrophobic NAC domain (Uéda et al., 1993).  
This region contains a sequence of amino acids (71-82) necessary and sufficient for       
α-synuclein self-assembly into amyloid fibrils (Giasson et al., 2001).  Recently the crystal 
structures of residues 68-78 (termed NACore), and residues 47-56 (PreNAC) were 
resolved by the use of micro-electron diffraction, revealing that strands in this region 
stack in-register into β-sheets that are typical of amyloid assemblies (Rodriguez et al., 
2015). 
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The C-terminal domain (96-140) is rich in negatively charged amino acids 
(contains 10 glutamate and 5 aspartate residues) and was originally proposed to be 
essential for maintaining the solubility of the protein.  The presence of 5 proline residues, 
which are known to induce turns and disrupt secondary protein structure, suggested that 
this region is devoid of secondary structure (George et al., 1995; Ulmer et al., 2005).  
However, the C-terminus was shown to form transient, long-range interactions with the 
N-terminus resulting in the formation of multiple compact monomeric structures 
(Bertoncini et al., 2005a; Dedmon et al., 2005).  These compacted structures of               
α-synuclein are temperature sensitive and are resistant to aggregation.  The data also 
indicated that at elevated temperatures the C-terminus assumes an extended conformation 
that liberates N-terminal associations and enables aggregation (Bertoncini et al., 2005b; 
Dedmon et al., 2005).  Moreover, C-terminally truncated forms of α-synuclein aggregate 
faster than full length protein (Hoyer et al., 2004; Li et al., 2005b).  Truncated α-
synuclein has been detected in the brains of both control (non-disease) and PD patients.  
Cleavage of full-length protein at residues D115, D119, N122, D125 and Y133 was 
documented in α-synuclein extracted from LBs (Anderson et al., 2006).  
The C-terminus appears to be important for the interaction of α-synuclein with 
other proteins and for the interaction with small molecules (Burre et al., 2012; Burré et 
al., 2010; Conway et al., 2001; Mazzulli et al., 2006; Souza et al., 2000b; Woods et al., 
2007).  Additionally, it contains the major sites of metal binding and post-translational 
modifications.  Binding of iron, copper, and other metals has been shown to influence α-
synuclein function and aggregation (Uversky et al., 2001a).  Addition of Fe(III), but not 
Fe(II) to preformed oligomers of α- synuclein accelerates aggregation, raising 
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the question of metal binding at different points during the aggregation process (Kostka 
et al., 2008).  Cu(II) is unique among metals at accelerating aggregation of α-synuclein at 
physiologically relevant concentrations.  The sole histidine residue H50 in α-synuclein 
was found to be critical for Cu(II) binding (Rasia et al., 2005) whereas other divalent 
metal ions, including Mn(II), Co(II), Ni(II) and Fe(II), preferentially bind to the C-
terminus of α-synuclein at residues D121, N122, and E123 (Binolfi et al., 2006).   
 
3.4.2 Post-translational modifications   
α-Synuclein undergoes a number of post-translational modifications, including N-
terminal acetylation, serine and tyrosine phosphorylation, lysine ubiquitination and 
tyrosine nitration (Oueslati et al., 2010; Barrett & Greenamayer 2015).  α-Synuclein 
purified under mild conditions is acetylated in the N-terminus.  The N-terminal 
acetylation may account for the formation of an oligomeric form of the protein with 
partial α-helical structure (Trexler and Rhoades, 2012).  However, semisynthetic 
production of N-terminally acetylated α-synuclein demonstrated that modified and 
unmodified versions of the protein share similar secondary structure, aggregation 
propensities, and membrane binding (Fauvet et al., 2012b).  NMR studies indicated that 
the first 12 residues undergo a chemical shift due to N-terminal acetylation.  This 
modification also appears to stabilize the helicity of the N-terminus within the context of 
the full-length protein, and increases the affinity of α-synuclein for lipids (Dikiy and 
Eliezer, 2014).  
Mass spectrometry-based methodologies revealed that α-synuclein extracted from 
human Lewy bodies was phosphorylated at S129 (Fujiwara et al., 2002).  An antibody 
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raised against phosphorylated S129 was then used to show that α-synuclein was 
phosphorylated at this site only in subjects with disease and that S129 phosphorylated     
α-synuclein was present only in the Triton-X- and Sarkosyl-insoluble, urea soluble 
fraction.  These data indicated that some form(s) of aggregated α-synuclein and not the 
soluble protein is targeted for phosphorylation at S129.  Indeed in vitro data showed that 
purified fibrils of α-synuclein are substrates for casein kinase 1 or 2 (Waxman and 
Giasson, 2008).  Other data indicated that polo-like kinase (PLK) 2-mediated 
phosphorylation of S129 increased autophagy-mediated degradation of α-synuclein, 
suggesting that phosphorylation may be a neuroprotective mechanism to accelerate 
clearance of aggregated protein (Oueslati et al., 2013).  In addition to the monomeric α-
synuclein, S129 phosphorylated bands with apparent molecular weight of 22 kDa and 29 
kDa were observed in the detergent insoluble extract (Hasegawa et al., 2002).  These 
bands were also immunoreactive with anti-ubiquitin antibodies suggesting that S129 
phosphorylated α-synuclein is also targeted for mono- and di-ubiquitination.  It has long 
been established that the core of Lewy bodies stains positive for both α-synuclein and 
ubiquitin whereas the surrounding halo is immunoreactive for α-synuclein (Hasegawa et 
al., 2002).  Of the 15 lysine residues in α-synuclein, the major sites of LB-derived α-
synuclein undergoing ubiquitination were residues K12, K21, and K23 (Anderson et al., 
2006; Hasegawa et al., 2002; Sampathu et al., 2003).  
A number of spectroscopic methodologies (CD and NMR) were employed to 
explore the effect of S129 phosphorylation on the structure of α-synuclein.  CD data 
revealed that phosphorylation of S129 did not affect secondary structure, such that both 
non-phosphorylated and phosphorylated S129 exhibited random coil structure 
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(Paleologou et al., 2008).  NMR data revealed a number of chemical shifts that occur due 
to phosphorylation.  While the residues surrounding S129 exhibited the greatest 
perturbation, residues 1-90 also exhibited detectable chemical shifts (Paleologou et al., 
2008)  This likely reflects the previously documented long-range interactions of the C- 
and N-termini.  The potential effects of phosphorylation of S129 on the structure of the 
protein were not faithfully reproduced by mutation of S129 to either E or D, two common 
phosphomimics used to study the structural consequences of phosphorylation.  For 
example, phosphorylation at S129 increased the hydrodynamic radius of the protein, 
whereas S129 E/D mutants did not (Paleologou et al., 2008).   
Subsequent studies found additional sites of phosphorylation.  Elevated levels of 
phosphorylated α-synuclein at residue S87 were detected in human brains with 
Alzheimer’s disease, Lewy Body disorders, and multiple system atrophy (Paleologou et 
al., 2010).  S87 phosphorylation alters the biophysical properties of α-synuclein, 
including inhibition of fibril formation and reduction in membrane binding (Paleologou 
et al., 2010).  Additionally, phosphorylated α-synuclein at residue Y125 was detected in 
Drosophila expressing human wildtype α-synuclein as well as in human brains, though 
levels were decreased in disease compared with aged-matched healthy controls (Chen et 
al., 2009). 
The proximity of the α-synuclein phosphorylation sites to the metal binding sites 
raised the question of how phosphorylation may affect metal ion interactions.  This was 
investigated by the use of C-terminal peptides containing residues 119-132 that were 
either unmodified, phosphorylated at Y125 or at S129 (Liu and Franz, 2005).  By 
exploiting the luminescence properties of Tb3+, it was found that phosphorylated 
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Y125 showed enhanced Tb3+ binding relative to wildtype or phosphorylated S129.  
Additionally, phosphorylated Y125 preferentially bound to trivalent rather than divalent 
metal ions.  To investigate this further, longer C-terminal fragments comprised of 
residues 107-140 that were either unmodified of monophosphorylated at Y125 or S129 
were tested for their affinity to various metal ions.  By using a fluorescence quenching 
assay, the dissociation constants of the metal ion complexes and the α-synuclein peptides 
were determined.  These data indicate that either phosphorylation at Y125 or S129 
increases the binding affinity for Cu (II) and Fe(II), but not Fe(III).  Furthermore, 
phosphorylated Y125 has a greater affinity for Pb(II) than wildtype, but phosphorylated 
S129 has an even greater affinity than phosphorylated Y125.  Additionally, tandem MS 
indicated that phosphorylation causes the metal ion binding sites to shift towards the C-
terminal end of α-synuclein (Lu et al., 2011). 
α-Synuclein within Lewy bodies is nitrated on all four tyrosine residues (Giasson 
et al., 2000).  Chemical nitration of α-synuclein results in the formation of both tyrosine 
nitrated monomers and nitrated dimers (Souza et al. 2000b).  Immunoelectron 
microscopy confirmed that nitrated monomers and dimers are incorporated into amyloid 
fibrils.  Purified nitrated α-synuclein monomer by itself was unable to form fibrils, 
whereas the nitrated dimer accelerated aggregation of unmodified α-synuclein (Hodara et 
al., 2004).  Additionally, nitration at residue Y39 in the N-terminus decreased binding to 
synthetic vesicles and prevented the protein from adopting α-helical conformation 
(Hodara et al., 2004).  These observations were recently confirmed and elegantly 
expanded by the generation of site-specifically nitrated α-synuclein using protein 
semisynthetic chemistries (Burai et al. 2015).  Using the synthetic nitrated α-
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synuclein the data showed that nitration did not interfere with phosphorylation of S129 
by PLK3 and reaffirmed that intermolecular interactions between the N- and C-terminal 
regions of α-synuclein are critical in directing nitration-induced oligomerization of α-
synuclein (Burai et al. 2015).   
 
3.4.3 Native conformation(s) of α-synuclein   
Figure 3.2 depicts the rapid growth in the number of publications identified in 
PubMed using the term synuclein and highlights key studies that explored the native 
structure and conformation of the protein.  Early biochemical studies of α-synuclein 
isolated from bacterial expression systems or α-synuclein expressed in rodent tissues 
indicated   that   it  is  monomeric  with   limited   secondary   structure.    Electrophoretic 
 
  
 
Figure 3.2: The graph depicts the number of publications retrieved from PubMed using the 
search term “alpha synuclein” from a single publication in 1998 to 862 in 2015.  Significant 
milestones that examined the native structure and conformations of α-synuclein are displayed. 
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separation of α-synuclein purified without heating on 6, 10, or 14% acrylamide gels 
estimated an apparent molecular weight of 20±3 kDa.  However, the values of 
sedimentation coefficient (S20,w = 1.7S), stokes radius (34 Å), analysis on native gels and 
derivation of the frictional coefficient (f/fo=2.09) indicated an apparent molecular weight 
in the range 57-58 kDa (Weinreb et al., 1996).  To reconcile this apparently anomalous 
behavior it was proposed that monomeric α-synuclein achieves minimal structure in 
simple solutions and this rather extended unstructured conformation resembles a globular 
protein with a larger apparent molecular weight.  This assumption was further 
corroborated by examination of purified monomeric α-synuclein by CD, FTIR and small 
angle X-ray scattering, which failed to identify significant secondary structural features.  
Furthermore, minimal shifts in the spectroscopic features of α-synuclein were observed 
when the protein was placed in solutions that would increase hydrophobicity and 
neutralize negative charges indicating that the protein is natively unstructured, joining a 
growing group of proteins sharing similar biochemical and biophysical characteristics 
(Uversky et al., 2001b).  NMR and CD data, however, indicated that α-synuclein assumes 
increasingly folded secondary structure when exposed to conditions that promote 
aggregation (low pH and high temperature) or upon interaction with phospholipids.  
Collectively these data indicated that native α-synuclein is primarily an unstructured 
monomer, which can assume different compact conformations that resist aggregation, 
adopts α-helical conformation upon binding to lipids and undergoes conformational 
changes prior to oligomerization and formation of amyloid fibrils (Uversky et al., 2001b).  
However, the methodologies employed to quantify the molecular weight of α-synuclein 
in these elegant studies were not based on first principles and therefore a lingering 
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uncertainty remains regarding the native size of the protein.  Moreover, crosslinking 
experiments in both intact cells expressing α-synuclein and lipid-free lysates revealed the 
stabilization of high molecular weight α-synuclein multimers (consistent with dimers, 
trimers, and larger multimers).  These multimers were not reduced by dilution of lysates 
before crosslinking, nor by reducing the concentration of crosslinker from 1 mM to 8 
µM, suggesting that they represented endogenous protein complexes (Cole et al., 2002).   
Examination of the α-synuclein native state was reignited in 2011 with the 
publication of results indicating that α-synuclein exists natively as a tetramer, rather than 
a monomer.  Methodologies that are based on first principles were employed to examine 
the molecular weight and size of α-synuclein extracted under non-denaturing conditions 
from human red blood cells.  Analytical ultracentrifugation produced a sedimentation 
equilibrium value of 4.78 S, indicating a molecular weight of 57.8 kDa.  Analysis of 
particle geometry by scanning transmission electron microscopy revealed the presence of 
roughly spherical molecules with a diameter of approximately 3.0-3.5 nm.  Automated 
sampling of 1000 α-synuclein particles showed a distribution of molecular weights 
between 10 and 175 kDa with a peak distribution at 55 kDa.  These findings constitute 
the most direct measurements of the native molecular weight of α-synuclein.  The 
tetrameric species were shown to have α-helical conformation and were resistant to 
aggregation (Bartels et al., 2011).   
Complimentary observations were made using recombinant GST-tagged             
α-synuclein purified from bacterial expression systems under non-denaturing conditions.  
Single-particle electron microscopy of purified α-synuclein revealed complexes of sizes 
and internal geometries consistent with trimers and dimers, which were 
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corroborated by measurements of the hydrodynamic radii and elution on native state 
PAGE.  As observed previously, these species were more resistant to aggregation than 
denatured monomer.  CD also showed that several α-synuclein mutations associated with 
early onset PD (A30P, E46K, A53T) exist in less ordered conformations than wildtype α-
synuclein.  These mutants were also more prone to aggregation (Wang et al., 2011).  
However, using the same α-synuclein construct that contains a 10-residue N-terminal 
extension, which forms multimers when isolated from E. coli, NMR studies indicated that 
only a small fraction of α-synuclein assembles into α-helical trimers and tetramers and 
the majority remains as a disordered monomer (Gurry et al., 2013).  These data indicated 
that several potential conformers of α-synuclein may exist in equilibrium.  The 
observation that α-helical trimers and tetramers constitute only a small fraction of the 
total α-synuclein may explain other studies in which in-cell NMR was used to probe for 
the structure of α-synuclein and reported primarily the presence of unstructured 
monomer.  NMR data of α-synuclein in intact cells failed to detect stable or highly 
populated α-synuclein multimers and confirmed the intrinsically disordered nature of the 
protein in E. coli regardless of its purification method (Binolfi et al., 2012).  Collectively 
these studies generated an apparent controversy and stimulated several additional studies 
that explored the native size and structure of α-synuclein.   
A re-examination of the native state of α-synuclein reasserted that the behavior of 
α-synuclein from various sources was consistent with a disordered monomer.  This 
behavior was observed with protein extracted and isolated under both denaturing and 
non-denaturing conditions.  CD spectra previously attributed to tetrameric assemblies 
were not reproduced using isolated monomer, but were replicated with the 
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addition of small unilamellar vesicles.  Natively isolated α-synuclein before or after 
boiling that disrupts secondary structure migrated as high molecular weight α-synuclein 
bands in native PAGE, which was attributed to the rather expanded size of the 
unstructured monomer in solution.  These findings reaffirmed that the majority of native 
α-synuclein is a monomer with minimal secondary structure (Fauvet et al., 2012a).  
Further support was provided by similar explorations in the mouse brain, which indicated 
that the predominant native form of α-synuclein is an unstructured monomer.  α-
Synuclein exhibited random coil structure in solution, readily aggregated over time, and 
adopted α-helical structure only upon membrane binding (Burré et al., 2013).   
α-Synuclein multimers were detected in postmortem non-diseased human brain 
using mild protein extraction methods, but no further purification.  These α-synuclein 
multimers had Stokes radii ranging from 33.2-37.5 Å, sedimentation coefficients ranging 
from 1.4S to 3.8S and apparent molecular weights ranging from 53-70 kDa in native 
gradient gels.  The multimers were detected by anti-α-synuclein antibodies that recognize 
different epitopes and the multimer identity was confirmed by mass spectrometry.  
Consistent with previous observations, melting point thermostability analysis showed 
progressive loss of the α-synuclein multimers and heating of the brain extracts above     
55oC collapsed the higher molecular weight α-synuclein conformers into the 53 kDa 
species, which corresponds to the unstructured monomer.  These data indicated the 
presence of α-synuclein conformers, defined as conformationally diverse α-synuclein 
multimers, in the human brain.  Therefore it appears that both monomer and metastable 
multimers coexist and that interactions with lipids, other proteins, or small molecules 
may transiently stabilize these species (Gould et al., 2014).  This was further 
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supported by controlled bimolecular fluorescence complementation methodologies in 
different cell types that found α-synuclein metastable conformers assembled in synapses.  
It was suggested that the function of these multimeric α-synuclein conformers is to 
restrict recycling of synaptic vesicles and thus reduce neurotransmitter release (Wang et 
al. 2014).   
Additional support for native multimeric species comes from recent studies in 
which serial purification of α-synuclein from non-pathological human cortical tissue was 
performed.  Removal of lysate components other than protein followed by sequential 
removal of proteins though size exclusion, anion chromatography, and thiopropyl 
sepharose 6b separation, resulted in the isolation of >90% pure α-synuclein.  Each step of 
serial purification resulted in a progressive loss of α-synuclein immunoreactive high 
molecular weight bands observed after disuccinimidyl glutarate crosslinking and SDS-
PAGE separation.  Analysis of α-synuclein secondary structure by CD found that the 
sequentially purified protein had greater α-helical content than the recombinant α-
synuclein.  However, a high degree of variability in secondary structure was observed 
between purified samples raising questions about the stability of these helical 
conformations (Luth et al., 2015).  Furthermore, crosslinking experiments conducted in 
brain tissue from mice expressing wildtype or A53T human α-synuclein in the absence of 
mouse α-synuclein showed that the A53T mutation reduced the presence of soluble 
multimeric α-synuclein (Dettmer et al., 2015). 
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3.5 Concluding remarks and perspectives 
Collectively the studies on the native structure indicate a remarkable 
conformational plasticity and structural flexibility of α-synuclein.  The ability of the 
protein to adopt N-terminal α-helical conformation through its association with lipids has 
been well documented.  The association with lipids has been shown to prevent fibril 
formation (Martinez et al., 2007; Zhu and Fink, 2003b) and may also stabilize 
physiological multimeric species that together with the monomer regulate SNARE 
complex assembly and recycling of synaptic vesicles (Burré et al., 2014; Wang et al. 
2014).  However, other groups have demonstrated a role for phospholipid membranes in 
promoting pathological α-synuclein aggregation, potentially by acting as a scaffold for 
amyloid nucleation.  This event may preferentially occur at low lipid to protein ratios, 
when monomeric α-synuclein is free in solution and can participate in nucleation 
(Galvagnion et al., 2015; Ysselstein et al., 2015).  
In Figure 3.3 we propose a model which incorporates and summarizes the existing 
knowledge regarding α-synuclein biology and structure.  The steady state levels of         
α-synuclein are carefully regulated by protein synthesis and removal by several pathways 
such as the ubiquitin-proteasome pathways and autophagy (Webb et al., 2003).  
Controlling the steady state levels of this protein by regulating synthesis and degradation 
may be the first critical defense in preventing aggregation.  Conformational change to    
α-helical rich structures, and stabilization of metastable multimers is achieved by specific 
interactions with vesicular phospholipids and proteins.  The sequestration of α-synuclein 
in association with membrane vesicles and with other proteins may be of critical 
importance   for   preventing  aggregation.    Therefore     these     dynamic     equilibria  
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Figure 3.3: Free energy landscape of possible α-synuclein conformers and multimeric 
assemblies.  The conversion of native α-synuclein to aggregation-competent monomers may 
depend on dissociation from stabilizing interactions with lipids and/or proteins as well as 
dissociation of the metastable tetrameric species.  α-Synuclein aggregation-competent monomers 
can then assemble into dimers and larger oligomeric conformers.  The generation of α-synuclein 
oligomers can rapidly lead to formation of stable amyloid fibrils, or ‘off-pathway’ amorphous 
aggregates, both of which have been observed in postmortem brain tissue from patients with PD 
and related disorders. 
 
maintain functionality and promote assemblies that are resistant to aggregation.  
Catastrophic events that may include inappropriate post-translational modifications will 
disassemble the multimers as well as transform aggregation-incompetent monomers to 
aggregation-competent species.  The first step in the pathway to amyloid fibril formation 
is the generation of a dimer that is either held together by hydrophobic interactions 
induced by increased conformational transition to β-sheet structure or upon covalent 
cross-linking.  Following this nucleation event (Wood et al., 1999) the hydrophobic patch 
of amino acids between residues 71-82 appears to be primarily responsible for allowing 
additional α-synuclein monomers to assemble to form oligomeric structures.  
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This transition is the committed rate limiting step for aggregation and must overcome a 
relatively large thermodynamic requirement that permits the conversion from an 
unstructured coil to organized β-sheet conformation.  Oligomers are soluble in aqueous 
buffers and can appear spherical or ring-like by atomic force and electron microscopy 
(Conway et al., 2000b; Lashuel et al., 2002).  Soluble, high molecular weight oligomers 
have been extracted from human brain tissue and their levels appear to be increased in 
PD brain (Sharon et al., 2003) as well as mouse models of α-synuclein aggregation (Tsika 
et al., 2010).  As oligomers grow, they reach an undefined critical length and are able to 
assume additional quaternary structure.  At this stage, these structures may continue to 
grow in linear β-sheets, forming polarized protofibrils and eventually fibrils. Fibrils may 
further arrange into protein inclusions although it remains unclear if other proteins within 
these inclusions anchor these fibrils.  Alternatively, oligomers may remain soluble by 
interacting with small molecules (Conway et al., 2001) or by incorporating post-
translationally modified α-synuclein molecules.  These structures remain “off the amyloid 
fibril pathway” and may constitute what has been described in human postmortem tissue 
as “dots” or “dust-like” amorphous aggregates (Braak et al., 2001; Duda et al., 2002).  At 
this juncture, it remains unclear which of these assemblies are toxic to neurons.  Recent 
data indicate that several conformationally distinct assemblies (possibly different strains) 
of α-synuclein generated in vitro will induce the aggregation of endogenous α-synuclein 
resulting in neurodegeneration (Guo et al., 2013; Luk et al., 2012; Peelaerts et al., 2015; 
Sacino et al., 2014).  The appreciation of different α-synuclein conformers and 
assemblies as well as their roles in disease may guide potential therapeutic approaches.  
For example, therapeutic strategies can be centered on preserving and stabilizing the 
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physiological multimeric conformers as well as preventing monomers from aggregating.  
Alternatively, sequestration and removal of aggregation-competent monomers and 
oligomers can be considered. 
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 A pathognomonic hallmark of idiopathic PD is the Lewy body, an intraneuronal 
inclusion containing aggregated α-synuclein.  Lewy pathology develops in circumscribed 
brain regions, and neurodegeneration occurs in several of these areas including the SN 
(Forno, 1996; Braak et al., 2003).  Coupled with the discovery that mutations and 
multiplications of the α-synuclein gene cause rare forms of familial PD (Goedert et al., 
2013), these defining features suggest that α-synuclein is a major player in PD 
pathogenesis.  The correlation between Lewy body inclusions and neuronal cell death is 
imperfect, however.  Not all neuronal populations that harbor α-synuclein inclusions also 
exhibit marked cell loss (Forno, 1996).  Furthermore the density of inclusions does not 
correlate well with clinical severity (Ross and Poirier, 2005).  Lewy bodies have also 
been found in the brains of some elderly asymptomatic individuals (Goedert et al., 2013).  
Mutations in LRRK2, a common cause of familial PD, are not always associated with 
Lewy pathology, and juvenile-onset parkinsonism typically develops in the absence of α-
synuclein inclusions (Goedert et al., 2013).  These observations highlight the need to 
better understand the role of α-synuclein aggregation in PD etiology, and raise the 
possibility of α-synuclein-independent disease mechanisms. 
 In sporadic PD, which constitutes the majority of cases, the presence of Lewy 
bodies in addition to smaller aggregates of α-synuclein has made it difficult to identify 
which species, if any, are primarily responsible for neuronal degeneration.  Lewy bodies 
and Lewy neurites could present enormous challenges to normal cellular functions, 
including protein degradation, axonal transport, and maintenance of the cytoskeleton 
(Norris et al., 2004).  It is possible that all neurons burdened with α-synuclein deposits 
are on a trajectory towards cell death, but due to region- and/or cell type-specific 
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factors, neuronal dysfunction and loss manifest with varying kinetics.  This may explain 
the imperfect correlation between Lewy pathology and neurodegeneration or clinical 
symptoms, and suggests that individuals with incidental Lewy body disease may have 
preclinical PD (Goedert et al., 2013).  Alternatively, inclusion bodies may serve to 
protect neurons by sequestering smaller α-synuclein aggregates such as oligomers or 
fibrils, for which there is increasing evidence of toxicity (Danzer et al., 2007; Karpinar et 
al., 2009; Tsika et al., 2010; Volpicelli-Daley et al., 2011; Winner et al., 2011; Luk et al., 
2012a).  In Chapter 2 of this thesis, I present evidence for a new mouse model of 
progressive SN neurodegeneration and locomotor deficit driven by α-synuclein toxicity.  
This model was used to examine the relationship of biochemically and histologically 
defined α-synuclein aggregates with disease, and I found that dopaminergic neurons 
degenerated in the absence of Lewy body-like inclusions.  Instead, the disease phenotype 
correlated with increased levels of oligomers, which bore similar conformations to 
neurotoxic oligomers generated in vitro.  Thus, α-synuclein aggregation in multiple brain 
regions may give rise to PD specifically through the formation of oligomers.  Moreover, 
the dependence of both the observed degeneration and oligomer species on dopamine 
suggests that catecholamines may enhance α-synuclein toxicity and confer heightened 
vulnerability to SN neurons. 
 Several genes linked to familial PD also implicate mitochondrial dysfunction in 
neurodegeneration of the SN and development of parkinsonian signs.  Genetic mutations 
in Parkin, PINK1, and DJ-1 may converge on a common pathway in which the normal 
maintenance and turnover of mitochondria is disrupted (Hernandez et al., 2016).  This 
may lead to energy depletion, and oxidative stress through increased production of 
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reactive oxygen species (Bose and Beal, 2016).  Dopaminergic neurons in the SN may be 
particularly susceptible to oxidative damage due to the normal metabolism and auto-
oxidation of dopamine (Graham, 1978; Fahn and Cohen, 1992).  In support of these 
mechanisms, complex I inhibitors such as MPTP induce oxidative stress and reproduce 
PD-like dopaminergic cell death in both humans and animal models (Dauer and 
Przedborski, 2003).  Knockout of Parkin, PINK1, or DJ-1 has been largely insufficient to 
induce SN neuron loss in mice (Blesa and Przedborski, 2014), although this may reflect 
the slow progression of autosomal recessive PD (Goedert et al., 2013).  Critically, the 
lack of Lewy body pathology in such cases of PD suggests that this form of the disease 
may be mechanistically distinct from the typical late-onset disorder.  Toxicity associated 
with α-synuclein aggregation may play a more central role in idiopathic PD, although a 
potential contribution of α-synuclein to mitochondrial impairment cannot be discounted 
since α-synuclein knockout mice are resistant to MPTP (Dauer et al., 2002).  The mouse 
model presented in Chapter 2 can be used to further investigate potential interactions 
between mitochondria, α-synuclein, and dopamine.  In addition, rescue of the 
degenerative phenotype by manipulation of putative disease mechanisms, for example 
through pharmacological or genetic disruption of toxic interactions or upregulation of 
neuroprotective pathways, will inform new strategies for PD treatment. 
 
4.1 The synergistic interaction between dopamine and α-synuclein drives SN 
neurodegeneration 
 In Chapter 2, my findings indicate that nigrostriatal degeneration is dependent on 
the convergence of two factors: elevated dopamine and expression of α-synuclein.  
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In the mouse brain neither of these factors alone was sufficient to induce neurotoxicity, 
suggesting that it is their specific interaction that is required.  Given the postulated role of 
dopamine in promoting oxidative stress (Graham, 1978; Fahn and Cohen, 1992; Jenner 
and Olanow, 1996; Stokes et al., 1999), it is somewhat surprising that long-term elevation 
of dopamine levels in NonTg mice did not result in dopaminergic nerve terminal or cell 
body loss.  Lentiviral-mediated expression of a dysregulated mutant TH achieved a 52% 
increase in total striatal dopamine content measured at 5 mpi.  It is possible that excess 
dopamine was well-tolerated due to compensatory upregulation of metabolic enzymes 
and transporters; indeed, there was a significant increase in DAT levels in these mice.  
Oxidative stress may be prevented if dopamine storage, release, and re-uptake 
mechanisms remain tightly coupled with dopamine levels, for example through the 
efficient cycling of excess dopamine into acidified vesicles where its kinetics of oxidation 
are much slower than in the cytosol.  To my knowledge, this is the first in vivo report of a 
sustained increase in dopamine synthesis and the effects on neuronal health.  Previous 
studies have shown that single, high dose injections of dopamine into the striatum of rats 
can be acutely toxic within the short timeframe of 10 days (Filloux and Townsend, 1993; 
Hastings et al., 1996; Rabinovic et al., 2000).  Other groups have demonstrated 
neurotoxicity associated with redistribution of endogenous dopamine to the cytosol by 
manipulation of VMAT2 or DAT in mice (Colebrooke et al., 2006; Caudle et al., 2007; 
Chen et al., 2008a; Masoud et al., 2015).  While dopamine has been implicated in PD 
pathogenesis, its precise role has remained poorly defined. 
 Despite the clear link between α-synuclein misfolding/aggregation and 
neurodegenerative disease in humans, it has been difficult to recapitulate these 
 101 
features in transgenic animal models.  The overexpression of human WT or familial 
mutant α-synuclein in mice has often resulted in a lack of inclusion pathology and 
neurodegenerative changes in the SN (Rathke-Hartlieb et al., 2001; Matsuoka et al., 
2001; Richfield et al., 2002; Giasson et al., 2002; Lee et al., 2002; Gispert et al., 2003; 
Gomez-Isla et al., 2003; Yavich et al., 2005; Martin et al., 2006; Emmer et al., 2011).  It 
is well-established that dopaminergic neurons are entirely spared in the A53T transgenic 
mice used in the present work (Giasson et al., 2002) and I also documented a normal 
complement of neuronal cell bodies and terminals and a lack of intraneuronal α-synuclein 
inclusions in the SN in these mice.  This may be related to several factors, including the 
fact that WT mouse α-synuclein allele has a threonine at position 53.  In vitro, mouse α-
synuclein fibrillizes more rapidly than human WT or A53T α-synuclein, and yet aged 
mice do not spontaneously develop α-synuclein inclusions or a PD-like disorder (Rochet 
et al., 2000).  It is likely that mice have evolved protective mechanisms against α-
synuclein aggregation, such as an enhanced ability to maintain α-synuclein in a 
physiological lipid- or protein-bound state, and that these mechanisms may counteract 
efforts to initiate disease by transgenic α-synuclein expression.  Given that age is the 
greatest risk factor for PD, another possibility is that the short lifespan of mice (typically 
1-2 years) does not allow adequate time for development of PD-like inclusions or 
neurodegeneration with α-synuclein overexpression. 
 Strikingly, elevating total striatal dopamine in A53T mice by TH-RREE lentiviral 
injection resulted in progressive nigrostriatal degeneration and a locomotor deficit, 
suggesting that dopamine dysregulation is a critical factor in α-synuclein mediated 
toxicity.  Following an early decrease in dopaminergic nerve terminals, A53T 
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TH-RREE mice exhibited a more severe loss of terminals and overt neuronal cell loss in 
the SN at five months after injection.  Moreover, there was a time-dependent decline in 
dopamine levels that led to a significant reduction in ambulation.  These findings are 
consistent with other studies in which dopamine and α-synuclein act synergistically to 
compromise cellular health.  In the case of VMAT2-deficient mice, loss of SN neurons 
was only observed in animals on a normal α-synuclein background, whereas identical 
reduction of VMAT2 in animals with an α-synuclein gene locus deletion did not result in 
cell loss (Specht and Schoepfer, 2001; Colebrooke et al., 2006; Caudle et al., 2007).  In 
rodent midbrain cultures, elevating cytosolic dopamine concentration reduced 
dopaminergic cell survival and this effect was dependent on α-synuclein (Mosharov et 
al., 2009).  Similarly, both dopamine and α-synuclein were required to induce cell death 
in human fetal dopaminergic cultures and SH-SY5Y cells (Xu et al., 2002).   
 The progressive nature of the phenotype in A53T TH-RREE mice in which 
dopaminergic terminals appear to undergo degeneration prior to cell bodies is supported 
by existing evidence that synapses are an early site of the disease process.  Autopsy 
reports as well as PET imaging studies in living PD patients suggest that, at the time of 
disease onset, the loss of striatal nerve terminals exceeds that of dopaminergic cell bodies 
(Cheng et al., 2010).  Axonal pathology containing α-synuclein has also been identified 
in PD and DLB (Galvin et al., 1999).  Consistent with the human data, expression of 
human α-synuclein in the rat SN induced synaptic dysfunction and axonal damage that 
preceded substantial cell loss (Chung et al., 2009; Lundblad et al, 2012).  My results 
show that at the early timepoint of 2.5 mpi, there is a documented 25% loss of 
dopaminergic nerve terminals in A53T TH- RREE mice, without an accompanying 
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reduction of neuronal cell bodies in the SN.  Axonal degeneration progresses such that 
dopaminergic innervation of the striatum falls to 62% of age-matched controls, and 
coincides with a 25% loss of neurons in the SN.  These data are in line with a disease 
mechanism that begins at the synapse, causes a ‘dying back’ of axons and a retrograde 
progression of neurotoxic events that ultimately lead to neuronal demise.  Indeed, the 
localization of both dopamine and α-synuclein to presynaptic terminals permits a direct 
interaction that may drive neurodegeneration. 
 
4.2 Oligomers are a potential point of convergence for dopamine and α-synuclein 
neurotoxicity 
 The aggregation of α-synuclein can produce several intermediate species and both 
fibrillar and non-fibrillar products, and it has been difficult to identify which species may 
be relevant to disease.  α-Synuclein oligomers are thought to be critical players in PD and 
other synucleinopathies (Ross and Poirier, 2005).  Oligomeric species have been 
identified and linked with toxicity in cell culture (Gosavi et al., 2002; Outeiro et al., 
2008) and animal models (Tsika et al., 2010; Winner et al., 2011), and appear to be 
increased in PD brain (Sharon et al., 2003).  Dopamine has been shown to promote 
α-synuclein oligomerization both in purified protein systems and cell cultures, through 
the non-covalent interaction of oxidized dopamine with the C-terminal 125-YEMPS-129 
motif in α-synuclein (Conway et al., 2001; Norris et al., 2005; Mazzulli et al., 2006; 
2007).  In Chapter 2, I report the novel finding that dopamine increases and modifies 
α-synuclein oligomers in the mouse brain, suggesting that dopamine may act as an 
enhancer of oligomer toxicity.  Presumably, these changes are mediated by cytosolic 
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dopamine, which could encounter and directly interact with α-synuclein, though the 
possibility of indirect mechanisms involving vesicular or extracellular dopamine cannot 
be excluded.  The relevant source of dopamine may be identified by manipulation of 
dopamine compartmentalization, for example by co-overexpression of VMAT2, which 
would be expected to mitigate α-synuclein oligomerization and neurodegeneration.  
 Consistent with dopamine-mediated stabilization of α-synuclein oligomers in 
vitro (Conway et al., 2001; Norris et al., 2005), elevating total striatal dopamine in A53T 
mice resulted in greater levels of oligomeric species.  It appears that these species were 
primarily generated from monomeric α-synuclein rather than larger aggregates, as 
monomer levels were significantly decreased and insoluble α-synuclein remained 
unchanged.  While it has been reported that dopamine is able to disaggregate α-synuclein 
fibrils (Li et al., 2004), this remains to be established and I did not find evidence of 
disaggregation in our mouse model.  Rather, it is more likely that dopamine acts to shift 
the dynamic equilibrium between monomers and oligomers in favor of the oligomeric 
state.  This could be achieved, for example, through direct interaction with α-synuclein 
oligomers, effectively removing them from the reaction, or by interaction with monomers 
such that they become aggregation-competent.  At present, the exact α-synuclein species 
with which dopamine interacts is unknown, although the presence of oxidized dopamine 
only in high molecular weight protein complexes extracted from A53T TH-RREE mice 
suggests that oligomers may be the likely target. 
 The oligomer species that result from the interaction of dopamine and α-synuclein 
in vivo assume both similar and distinct conformations from those previously observed.  
In the SN of A53T control mice, soluble oligomers with Stokes radii of up to 65 
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Å and apparent molecular weights ranging from 36 to 80 kD were identified, entirely 
consistent with previous biochemical characterization (Tsika et al., 2010).  These low Å 
oligomers were also found in A53T TH-RREE mice and appeared more abundant than in 
control mice.  Interestingly, larger species between 72-122 Å were present only in A53T 
TH-RREE mice, and were detected using multiple α-synuclein antibodies by both 
western blotting and immunoelectron microscopy.  The increase in oligomer size is in 
line with the previous observation by atomic force microscopy that larger diameter 
particles are produced in vitro when α-synuclein is incubated with dopamine than without 
(Follmer et al., 2007).  The significance of these findings is two-fold: for the first time it 
is demonstrated that dopamine promotes α-synuclein oligomerization in vivo, and 
moreover that the resultant species possess unique conformations.  The effects of 
dopamine on α-synuclein aggregation may produce neurotoxic species that ultimately 
drive neuronal cell death.   
 The toxicity of dopamine-induced α-synuclein oligomers was tested using 
recombinant protein that had been incubated with dopamine in vitro.  Soluble, high 
molecular weight oligomers resembling mouse-derived species were generated, and 
biochemical characterization recapitulated earlier findings (Norris et al., 2005; Cappai et 
al., 2005; Pham et al., 2009).  When applied to primary hippocampal cultures, the 
recombinant oligomers dose-dependently reduced neuronal viability, whereas neither 
oxidized dopamine nor monomeric α-synuclein had the same effect.  It is important to 
note that several aspects of this experimental paradigm diverge from the mouse model, 
including the non-dopaminergic cell type, and the extracellular application of oligomers.  
While hippocampal neurons do not mimic exactly the physiology and metabolism 
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of dopaminergic cells, they nonetheless offer a neuronal model in which to test the 
sufficiency of α-synuclein oligomers to incur toxicity.  The observation that dopamine-
induced oligomers were indeed toxic suggests that mechanisms of cell death downstream 
of the dopamine-α-synuclein interaction are not dependent on a dopaminergic cellular 
phenotype.  Regarding the exogenous source of α-synuclein oligomers, there is growing 
evidence that α-synuclein aggregates are secreted into the extracellular space and taken 
up by neighboring cells where they propagate disease pathology (Lee, 2008; Goedert et 
al., 2010).  There is also some evidence that dopamine promotes the secretion of 
α-synuclein oligomers (Lee et al., 2011).  Exogenous α-synuclein was detected inside 
neurons following oligomer treatment, suggesting that dopamine-induced species are able 
to translocate across cellular membranes and gain access to nearby cells.  A model for the 
intracellular formation of these species and possible mechanisms of cell-to-cell spread is 
outlined in Figure 4.1. 
 An alternative approach to test dopamine-induced oligomer toxicity is to disrupt 
the interaction between α-synuclein and dopamine, and examine if neuronal loss is 
mitigated.  This could be achieved by expressing a mutant α-synuclein lacking the C-
terminal 125-YEMPS-129 motif that is required for dopamine-mediated stabilization of 
oligomers (Norris et al., 2005; Mazzulli et al., 2007).  The small model organism 
C. elegans could be utilized for its powerful attributes: a genetically tractable system in 
which the entire genome has been sequenced and all neuronal identities have been 
mapped, a short generation time and lifespan, transparency which allows for the imaging 
of selected cells in living animals, and a repertoire of behaviors that have been associated 
with particular neurons or neurotransmitter systems (Corsi et al., 2015).   C.  elegans  
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Figure 4.1: Model for cell-to-cell transfer of dopamine-induced oligomers.  In disease, α-
synuclein monomers may be in dynamic equilibrium with aggregated species such as oligomers.  
Oxidized dopamine in the cytosol may directly interact with oligomers resulting in modified 
conformations with enhanced toxicity.  Dopamine-mediated stabilization of these species may 
shift the equilibrium towards the formation of additional oligomers, causing an increase in the 
total steady-state levels of oligomeric α-synuclein.  Dopamine-modified oligomers may propagate 
by disruption of synaptic vesicle membranes, allowing dopamine to leak into the cytosol and 
interact further with oligomers.  These species may also disrupt the plasma membrane gaining 
access to the extracellular space, and then directly enter neighboring neurons or become 
endocytosed, potentially via receptor-mediated endocytosis.  Oligomers may further escape 
endosomes by aberrant membrane interactions.  Alternatively, dopamine-modified oligomers may 
be actively released by dopaminergic neurons by exocytosis, and then taken up by other neurons.  
Due to the non-covalent nature of the interaction between α-synuclein and dopamine, oligomers 
may eventually be able to participate in the formation of Lewy bodies.  The cell-to-cell transfer of 
these species as well as other oligomeric conformers may therefore underlie the spread of 
pathology and neuronal demise in PD. 
 
that express human WT or A53T mutant α-synuclein in dopaminergic neurons have been 
generated and display dopamine neuron dysfunction and loss, as well as motor deficits 
(Lakso et al., 2003; Cao et al., 2005; Kuwahara et al. 2006; Cao et al., 2010).  Increasing 
cytosolic dopamine in WT α-synuclein-expressing worms by mutation of the VMAT2 
worm homolog was found to accelerate neurodegeneration.  Conversely, protec-
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tion from neuronal loss was reported for worms expressing WT α-synuclein and a non-
functional homolog of tyrosine hydroxylase and therefore do not synthesize dopamine 
(Cao et al., 2010).  These studies are entirely consistent with our findings in mice that 
indicate dopamine and α-synuclein act together to induce neurodegeneration.  To expand 
upon this work and test the role of a direct interaction between α-synuclein and 
dopamine, worms could be generated expressing human WT or A53T α-synuclein with 
the previously described C-terminal 125-FAAFA-129 substitution (Norris et al., 2005; 
Mazzulli et al., 2007).  These worms would be expected to show amelioration of the 
neurodegenerative phenotype and resistance to the neurotoxic effects of increasing 
cytosolic dopamine.  Moreover, an analysis of α-synuclein oligomers would be expected 
to correlate with disease, such that oligomer burden would be increased in α-synuclein/ 
VMAT2 mutants and decreased in both 125-FAAFA-129 and 125-FAAFA-129/VMAT2 
mutants.  To my knowledge, oligomeric α-synuclein has not been previously reported in 
worm models and these would therefore constitute novel biochemical findings. 
 
4.3 Putative mechanisms of toxicity for dopamine-induced α-synuclein oligomers 
 Several mechanisms of α-synuclein oligomer toxicity have been proposed, 
including disruption of membranes, endoplasmic reticulum stress, mitochondrial 
dysfunction, impairment of proteasomal and autophagic degradation, and induction of 
neuroinflammation (Roberts and Brown, 2015).  Dopamine-stabilized α-synuclein 
oligomers have been shown to impair chaperone-mediated autophagy and SNARE 
complex formation in vitro (Martinez-Vicente et al., 2008; Choi et al., 2013).  In addition, 
toxic α-synuclein aggregates are thought to propagate by seeding the conversion of 
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native α-synuclein into pathological conformations (Goedert et al., 2010).  In Chapter 2, 
dopamine-modified oligomers extracted from the mouse SN were found to be incapable 
of seeding the aggregation of recombinant α-synuclein in an in vitro assay.  This is in 
contrast to the efficient seeding activity observed for oligomers from control mice, 
suggesting that seeding-competent species are not retained following elevation of 
dopamine levels in vivo.  These data support the notion that dopamine promotes modified 
conformations of oligomers, with functional consequences that may be relevant to their 
toxicity.  Moreover, it appears that toxicity of these species is not mediated through a 
seeding mechanism, in contrast to previous reports from A53T mice showing that 
seeding-competent oligomers from the spinal cord induced neuronal injury in primary 
cultures whereas oligomers from the olfactory bulb that were found to inhibit aggregation 
were non-toxic (Tsika et al., 2010).  Clearly, further study is warranted to uncover the 
relationship between distinct oligomeric conformations, seeding competency, and 
neurotoxicity. 
 An alternative mechanism by which dopamine-induced α-synuclein oligomers 
may endanger neuronal health is through the disruption of cellular membranes.  
Recombinant α-synuclein oligomers have been shown to bind brain-derived and synthetic 
phospholipid membranes and permeabilize synthetic vesicles (Volles et al., 2001; Ding  
et al., 2002).  PD-linked A53T and A30P mutations exhibit an enhanced ability to 
permeabilize vesicles in vitro (Volles et al., 2002).  In some cases, recombinant 
oligomers have displayed ring-like morphologies by electron microscopy and atomic 
force microscopy, suggesting that membrane disruption may occur through a pore-
forming mechanism (Conway et al., 2000b; Lashuel et al., 2002; Ding et al., 2002).  
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Consistent with aberrant membrane interactions, α-synuclein oligomers (in one study, 
with annular morphology confirmed) have been shown to increase intracellular calcium 
levels and induce caspase activation and cell death when applied to primary neuronal 
cultures or SH-SY5Y cells (Danzer et al., 2007; Angelova et al., 2016).  The ability of 
dopamine-induced oligomers to cause calcium dysregulation has not been explored, 
although calcium and α-synuclein were both required for neuronal death in midbrain 
cultures following an increase in cytosolic dopamine levels (Mosharov et al., 2009).  
To test if recombinant α-synuclein oligomers generated in the presence of 
dopamine are able to elevate intracellular calcium, primary hippocampal neurons were 
exposed to oligomer preparations following pre-loading with Fluo-4 AM calcium-binding 
dye (see Appendix for detailed methods).  The extracellular bath contained physiological 
concentrations of calcium (1 mM).  Administration of a toxic dose of dopamine-
incubated α-synuclein (1 μM) resulted in an approximately 3% increase in fluorescence 
within 5 seconds, and fluorescence remained elevated for at least an additional 15 
seconds (Figure 4.2).  Interestingly, this effect was observed in axons (Figure 4.2a-b) and 
not in cell bodies (Figure 4.2c-d).  Equivalent doses of PBS or monomeric α-synuclein 
were incapable of producing the same response, indicating that the rise in intracellular 
calcium was mediated by oligomers.  Furthermore, omission of extracellular calcium 
abolished the effect in axons, consistent with oligomer-mediated disruption of membrane 
integrity and calcium influx (Figure 4.2a-b).  Further investigation is necessary, however, 
to exclude the possibility of calcium entry through voltage-gated calcium channels or 
glutamate receptors.  These data suggest that dopamine-induced α-synuclein oligomers 
can interact with cellular membranes and disturb calcium homeostasis.  Entirely 
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consistent with our findings is prior evidence showing that seeding-incompetent α-
synuclein oligomers induced calcium influx and cell death in SH-SY5Y cultures while 
oligomers that were capable of seeding had no effect on calcium or cell viability (Danzer 
et al., 2007).  Follow-up experiments could examine the relationship of internalized 
oligomers with intracellular membranes and calcium stores.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Dopamine-induced α-synuclein oligomers cause calcium dysregulation in 
primary neurons.  Hippocampal neurons at 7 days in vitro were pre-loaded with Fluo-4 AM dye 
and treated with 1 μM α-synuclein oligomer (Olig) or equivalent doses of monomer (Mon), 
ionomycin (Ionomyc), or PBS.  Representative traces of fluorescence intensity before and after 
the time of treatment (indicated by the arrows) are shown.  Oligomers induced a significant 
increase in fluorescence specifically in axons (a-b) and not in cell bodies (c-d).  Exclusion of 
calcium from the extracellular bath (Olig -Ca) eliminated the effect of oligomers on axons, 
suggesting that oligomers allow calcium entry into cells.  The data are presented as mean ± s.e.m.  
(Axons, n = 3 except n = 4 for PBS and Olig; Cell bodies, n = 3 except n = 4 for Olig and n = 2 
for Ionomycin; one-way ANOVA with Tukey’s correction for multiple comparisons).  ***P < 
0.001.  DEM and HI designed the experiments, VXT collected the data, and VXT and DEM 
analyzed the results. 
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4.4 Is L-DOPA therapy toxic? 
 Since the discovery that striatal dopamine is severely depleted in PD patients 
(Ehringer and Hornykiewicz, 1960), followed immediately thereafter by the first clinical 
use of L-DOPA to replenish dopamine levels (Birkmayer and Hornykiewicz, 1961), 
L-DOPA has become the gold standard of PD treatment.  Undeniably, the resulting 
symptomatic relief has markedly improved patients’ quality of life.  However, due to the 
notion that dopamine may be neurotoxic, there has been a widespread practice of ‘DOPA 
sparing’ that delays administration of the drug until more advanced stages of disease 
(Caudle et al., 2008).  It is therefore of utmost importance to determine if L-DOPA has 
any deleterious effects, in order to inform therapeutic approaches and ensure that patients 
receive the best quality of care.   
At present, there is no conclusive evidence indicating that L-DOPA therapy 
accelerates PD progression (Olanow, 2015).  A number of studies have been conducted in 
PD patients to test the question of L-DOPA toxicity, including trials based on clinical 
outcome (Diamond and Markham, 1990; Fahn et al., 2004; Gray et al., 2014), 
neuroimaging markers (Parkinson Study Group, 2002; Whone et al., 2003; Fahn et al., 
2004), and postmortem analyses (Parkkinen et al., 2011).  With the exception of the 
neuroimaging studies, which found that L-DOPA was associated with an accelerated 
decline in dopaminergic markers (Parkinson Study Group, 2002; Whone et al., 2003; 
Fahn et al., 2004), the consensus has been that L-DOPA either does not affect PD 
progression or in some cases may actually be neuroprotective.  However, the results of 
these studies are called into question by the significant limitations in their designs and 
methodologies.  Moreover, the symptomatic relief provided by L-DOPA is likely a 
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confounding factor in the assessment of underlying neuronal health and disease 
progression.  Thus, the issue of L-DOPA toxicity has unfortunately remained unresolved 
(Olanow, 2015).   
 By the time PD patients manifest motor symptoms and receive L-DOPA 
treatment, a significant number of dopaminergic neurons in the SN have already been 
lost.  In addition, evidence from PD brains suggests that dopaminergic terminals succumb 
to disease even earlier than neuronal cell bodies (Cheng et al., 2010), as is also the case in 
our mouse model, indicating that much of the disease process has occurred long before  
L-DOPA therapy is initiated.  While a role for L-DOPA in advancing neurodegeneration 
cannot be ruled out, my findings are instead more relevant to the etiology of PD, pointing 
to a potential mechanism for the initial demise of dopaminergic neurons involving the 
aberrant interaction of oxidized dopamine with α-synuclein. 
 
4.5 Concluding remarks 
 A unifying theory of neurodegeneration in PD must account for several features 
of the disease: the loss of dopaminergic neurons in the SN and the relative sparing of 
dopaminergic neurons in the neighboring ventral tegmental area (VTA), the loss of non-
dopaminergic cells in other brain regions such as the dorsal motor nucleus of the vagus 
and the nucleus basalis of Meynert, and the presence of α-synuclein-positive inclusions in 
both degenerating and non-degenerating neuronal populations.  The work presented in 
this thesis offers clues as to the disease mechanisms that may give rise to these features, 
and points to novel directions for future research.   
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As proposed in Chapter 3, PD may begin when catastrophic events occur allowing 
native α-synuclein to become aggregation-competent.  These could include age-related 
deterioration of proteostasis pathways, such as proper folding of α-synuclein by 
chaperones or degradation of improper conformations (Balch et al., 2008).  Following 
escape from protein quality control mechanisms, α-synuclein may aggregate into 
oligomers and fibrils, eventually forming Lewy body inclusions and Lewy neurites.  This 
may occur independently in different brain regions, or as growing evidence suggests, may 
arise through prion-like transmission of α-synuclein across synaptic connections (Goedert 
et al., 2010).  Different oligomer species can have different levels of toxicity (Danzer et 
al., 2007; Tsika et al., 2010), and region-specific factors may determine whether toxic 
oligomers are able to form and induce neurodegeneration.  In catecholaminergic regions 
such as the locus coeruleus and SN, oxidized cytosolic dopamine may act on oligomers 
and/or monomers resulting in particularly damaging oligomeric conformations.  These 
species may then induce cell death potentially through aberrant membrane interactions 
and disruption of calcium homeostasis.  SN neurons may be more susceptible to calcium 
dysregulation than VTA neurons due to their dependence on calcium for pacemaking and 
lower intrinsic calcium buffering capacity (Surmeier et al., 2013). 
Overall, this thesis provides four novel findings: First, the toxicity of a sustained 
elevation in striatal dopamine was tested for the first time, and surprisingly, was 
insufficient to produce dopaminergic cell death.  Second, and in stark contrast, raising 
dopamine levels in the context of higher α-synuclein expression resulted in progressive 
nigrostriatal degeneration and a locomotor deficit.  Third, for the first time in vivo, 
dopamine was shown to promote α- synuclein oligomerization yielding 
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species with unique conformations and activity.  Lastly, calcium dysregulation was 
implicated as a potential mechanism of dopamine-modified oligomer toxicity.                
α-Synuclein oligomers arising from the pathological interaction with dopamine may be 
an important new target in the design of disease-modifying therapies. 
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APPENDIX 
 
Materials and Methods 
Measurement of intracellular calcium was performed as previously described 
(Danzer et al., 2007).  Briefly, following one week in culture, cells were washed with 
Ringer buffer containing 130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 2 mM 
KH2PO4, 5 mM glucose, and 20 mM HEPES.  Cells were loaded for 60 min with 2 µM 
cell-permeable Fluo-4 AM (Thermo Fisher) in Ringer buffer, then washed with Ringer 
buffer, incubated at RT for 30 min, and washed again.  Cells were treated with 1 µM 
dopamine-incubated α-synuclein (from day 4-6 of in vitro aggregation) or control 
treatments.  For each well, fluorescence imaging was conducted in the same field of view 
for 30 seconds prior to treatment and for up to 5 min total.  Intensity measurements were 
obtained with MetaMorph software (Molecular Devices) and the baseline was calculated 
as the average intensity in the 10 seconds prior to treatment.  The ΔF/F was calculated as 
(maximum peak height - baseline) / baseline.  To determine calcium source, calcium was 
excluded from the Ringer buffer and experiments were performed as described above. 
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